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ABSTRACT 
As anticancer treatment becomes more effective, a larger number of patients survive 
to cancer and the long-term side effects of anticancer therapy become an increasingly 
important issue. The ideal anticancer drug with maximal activity and neglectful toxicity to 
non-cancer cells is not yet found. Thus, anticancer treatment side effects still affect healthy 
organs. Mitoxantrone (MTX) has been used in patients with advanced breast cancer, 
prostate cancer, acute leukaemia, lymphoma and in multiple sclerosis. Cardiotoxicity 
leading to heart failure is a serious side effect that can affect up to 18% of MTX-treated 
patients, although its’ cardiotoxicity mechanisms are poorly known. The toxicity of the 
metabolites of anticancer drugs has been proved to be, at least, partially responsible for 
their reported cardiotoxicity. Regarding MTX, data regarding the synthesis and toxicological 
evaluation of its metabolites are scarcely available. Therefore, this work aims to synthetize 
MTX naphthoquinoxaline metabolite and to assess the toxicity of MTX and of the 
synthetized metabolite of MTX in an in vitro model.  
The synthesis of MTX naphthoquinoxaline metabolite was accomplished by the 
horseradish peroxidase (HRP) catalyzed H2O2 oxidation. With the enzymatic oxidation of 
MTX, several derivatives could be observed by chromatographic analysis, and two purified 
derivatives were isolated and identified as naphthoquinoxaline (NAPHT), a well-known 
metabolite of MTX, and naphthoquinoxaline dicarboxylic acid (NAPHTdi). In this study, 
several spectroscopic methods for the identification of the metabolites obtained in the 
synthesis were performed, namely infrared, high performance liquid chromatography- with 
diode array detector, proton nuclear magnetic resonance, and high resolution mass 
spectrometry. The purity obtained was 97% for NAPHT and 75% for NAPHTdi. Moreover, 
the toxicological evaluation of MTX and of the synthetized metabolite, NAPHT, was 
performed in differentiated H9c2 myocytes. The effects toward energetics, mitochondria, 
nuclei and lysosomes, and cell death mechanisms were primarily focused. H9c2 cells were 
differentiated using Dulbecco's Modified Eagle Medium supplemented with 10 nM retinoic 
acid (RA) and 1% foetal bovine serum (FBS) for 7 days (medium changed every two-days). 
After the differentiation protocol, cells were incubated with MTX (0.01 µM to 5 µM) or 
NAPHT (1 to 5 µM) for two time-points (24 and 48h), and cytotoxicity tests [lactate 
dehydrogenase leakage (LDH) assay, the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl 
tetrazolium bromide (MTT) assay and the neutral red (NR) uptake assay] were performed. 
Phase contrast microscopy and several staining’s were also used to evaluate cytotoxicity. 
Moreover, adenosine triphosphate (ATP) levels were assessed after MTX or NAPHT 
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exposure. For the higher concentrations of MTX (1, 2, and 5 µM), cytotoxicity was time- and 
concentration-dependent in all assays, being the NR assay more sensitive for the MTX toxic 
effects in H9c2 differentiated cells. On the other hand, for NAPHT (1, 2, and 5 µM), 
cytotoxicity was time- and concentration-dependent in all assays, being the LDH leakage 
assay the most sensitive test. Phase microscopy allowed observing that MTX and NAPHT 
caused cell damage, being more evident in the MTX incubation and in the longer time-point. 
Neither MTX nor NAPHT incubation resulted in evident signs of apoptosis after 24 or 48h 
incubation. Several pharmacological active molecules were used in an attempt to elucidate 
the mechanisms involved in MTX- and/or NAPHT-induced cardiotoxicity. N-acetyl cysteine 
(antioxidant), buthionine sulphoximine (inhibitor of gamma-glutamylcysteine synthetase), 
cycloheximide (protein synthesis inhibitor), L-carnitine (mitochondrial enhancer) and Ac-
LETD-CHO (a broad caspase inhibitor) did not revert any of the MTX-induced cytotoxicity. 
Cytochrome P450 (CYP450) inhibitors, namely metyrapone and 1-aminobenzotriazole, 
were also used to evaluate the role of CYP450 towards MTX cytotoxicity. None of the 
compounds altered the cytotoxicity caused by MTX in H9c2 cells. Nevertheless, 3-
methyladenine (an autophagy inhibitor) gave a partial protection against the MTX and 
NAPHT observed cytotoxicity in the NR cell assay. Assessment of mitochondrial 
transmembrane potential in differentiated H9c2 cells incubated with 2 and 5 μM of MTX or 
NAPHT (2 and 5 µM) for 12h showed significant effects: there was an evident decrease in 
mitochondrial potential observed by fluorescent microscopy in both drugs. To understand if 
MTX and NAPHT had any effects on cellular energetics, intracellular ATP levels were 
measured in H9c2 cells exposed to MTX and NAPHT for 24h. In the NAPHT tested 
concentrations (2 and 5 µM), no significance changes were detected. In the cells incubated 
with the MTX (2 and 5 µM), a significant increase of ATP levels was observed, suggesting 
an adaptive response of H9c2 cells towards MTX. 
In conclusion, the isolation and structure characterization of NAPHT was 
accomplished and additionally, the isolation of a possible oxidation product of MTX, 
NAPHTdi, was isolated and characterized for the first time. Both MTX and NAPHT caused 
cardiotoxicity in micromolar concentrations in H9c2 cells, being autophagy involved. The 
cytotoxicity assays used show different sensitivities for both drugs. MTX and NAPHT 
caused a significant decrease of mitochondrial membrane potential in differentiated H9c2 
cells. Moreover, ATP levels were affected in a different manner after MTX and NAPHT 
incubation, revealing that these two drugs may impair cellular pathways in a dissimilar 
manner. 
 
Keywords: Mitoxantrone; Naphthoquinoxaline; Cardiotoxicity; H9c2 differentiated 
cells; Autophagy.   
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RESUMO 
Atualmente, o tratamento anticancerígeno tem-se tornado mais eficaz, registando-
se maiores taxas de sobrevivência. Desta forma, os efeitos adversos a longo prazo da 
terapêutica anticancerígena apresentam cada vez maior impacto. A terapêutica 
anticancerígena ideal com a máxima atividade e poucos ou nenhuns efeitos adversos ainda 
não foi encontrada, pelo que a terapêutica anticancerígena ainda hoje afeta os tecidos 
saudáveis. A mitoxantrona (MTX) tem sido usada em pacientes com cancro da mama 
avançado, cancro da próstata, leucemia aguda, linfoma e na esclerose múltipla. A MTX 
apresenta como efeito secundário a cardiotoxicidade, sendo que a insuficiência cardíaca é 
um dos efeitos mais graves que pode afectar até 18% dos pacientes tratados com MTX. 
Os mecanismos de cardiotoxicidade causada pela MTX são ainda hoje pouco conhecidos. 
A metabolização dos fármacos anticancerígenos tem sido demonstrada como parcialmente 
responsável pela cardiotoxicidade causada por estes fármacos. Relativamente à MTX, os 
dados são escassos, quer relativamente à síntese, quer à avaliação toxicológica dos seus 
metabolitos. Este trabalho teve como objetivos sintetizar o metabolito naftoquinoxalina da 
MTX e avaliar a toxicidade da MTX e deste metabolito in vitro. A síntese do metabolito 
naftoquinoxalina da MTX foi concretizada através da oxidação catalisada pela peroxidase 
de rábano na presença de H2O2. A oxidação enzimática da MTX permitiu obter vários 
derivados, como confirmado por análise cromatográfica. Desses derivados, dois 
compostos foram isolados, purificados e identificados como sendo a naftoquinoxalina 
(NAPHT) e o ácido dicarboxílico da naftoquinoxalina (NAPHTdi). Vários métodos 
espetroscópicos foram usados para a identificação dos derivados obtidos, nomeadamente 
infravermelho, cromatografia líquida de alta eficiência com detector de sistema de díodos, 
ressonância magnética nuclear protónica e espetrometria de massa de alta resolução. A 
pureza obtida foi de 97% para NAPHT e 75% para o NAPHTdi. Posteriormente, a MTX e a 
NAPHT foram avaliados toxicologicamente. Esta avaliação foi feita em células H9c2 
diferenciadas. Os ensaios realizados focaram principalmente os efeitos nas mitocôndrias, 
núcleo e lisossomas, assim como nos mecanismos de morte celular. As células H9c2 foram 
diferenciadas com meio de cultura Dulbecco Modified Eagle Medium suplementado com 
10 nM de ácido retinóico e 1% de soro fetal bovino, durante 7 dias (meio mudado a cada 
dois dias). Após o protocolo de diferenciação, as células foram incubadas com a MTX (0,01 
μM até 5 μM) e NAPHT (de 1 a 5 μM) durante 24 ou 48 horas. Após a incubação com as 
moléculas, foram realizados os seguintes testes de citotoxicidade: ensaio da libertação da 
lactato desidrogenase, da redução do brometo de 3-[4,5-dimetil-tiazol-2-il]-2,5-
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difeniltetrazólio a formazano (ensaio de redução do MTT) e o ensaio da incorporação do 
vermelho neutro. A microscopia de contraste de fase, assim como várias colorações, foram 
também usadas para avaliar a citotoxicidade. Além disso, os níveis de trifosfato de 
adenosina foram determinados após exposição a MTX ou NAPHT.  
Para as concentrações mais elevadas de MTX (1, 2 e 5 μM), a citotoxicidade, em 
todos os ensaios, foi dependente da concentração e do tempo. O ensaio da incorporação 
do vermelho neutro foi o mais sensível para os efeitos tóxicos da MTX em células H9c2 
diferenciadas. Por outro lado, a citotoxicidade causada pela NAPHT (1, 2 e 5 μM) foi 
também dependente da concentração e do tempo, em todos os ensaios realizados, sendo 
o ensaio da libertação da lactato desidrogenase o mais sensível aos efeitos tóxicos da 
NAPHT. Nem a incubação com a MTX nem com a NAPHT levaram a sinais evidentes de 
apoptose após 24 ou 48 horas. Várias moléculas farmacologicamente ativas foram 
utilizadas, numa tentativa de elucidar os mecanismos envolvidos na cardiotoxicidade 
induzida pela MTX e/ou da NAPHT. A N-acetilcisteína (antioxidante), a sulfoximina de 
butionina (inibidor de gama-glutamilcisteína sintetase), a ciclo-heximida (inibidor de síntese 
proteica), a L-carnitina (protector mitocondrial) e o Ac-LETD-CHO (um inibidor das 
caspases) foram usados e nenhum conseguiu reverter a citotoxicidade causada pela MTX. 
Os inibidores do citocromo P450, nomeadamente, a metirapona e o 1-aminobenzotriazol, 
foram também utilizados para avaliar o papel do metabolismo via citocromo P450 na 
citotoxicidade da MTX. Nenhum dos compostos mencionados foi capaz de alterar a 
citotoxicidade induzida pela MTX. No entanto, o inibidor de autofagia, 3-metiladenina, levou 
a uma protecção parcial contra a citotoxicidade causada pela MTX e pela NAPHT, no 
ensaio do vermelho neutro. A avaliação do potencial transmembranar mitocondrial nas 
células H9c2 diferenciadas incubadas com 2 e 5 μM de MTX e NAPHT durante 12 horas 
demonstrou que ambos os compostos causaram um decréscimo evidente no potencial 
mitocondrial. Além disso, os níveis intracelulares de trifosfato de adenosina foram avaliados 
nas células H9c2 expostas a MTX e NAPHT durante 24 horas. Nas concentrações de 
NAPHT (2 e 5 µM) testadas não foram detetadas alterações significativas. Nas células 
incubadas com MTX (2 e 5 µM) houve um aumento significativo dos níveis intracelulares 
de trifosfato de adenosina, o que sugere uma resposta adaptativa das células após 
exposição à MTX.  
Em conclusão, o isolamento e caraterização da NAPHT, assim como o isolamento 
pela primeira vez do NAPHTdi foram concretizados nesta tese. Além disso, verificou-se 
que tanto a MTX como a NAPHT causam cardiotoxicidade em concentrações micromolares 
estando a autofagia envolvida. Os ensaios de citotoxicidade usados apresentaram 
diferentes sensibilidades para ambos os compostos. A MTX e a NAPHT causaram uma 
redução significativa do potencial de membrana mitocondrial nas células H9c2 
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diferenciadas. Os níveis de trifosfato de adenosina foram afectados de forma diferente nas 
células H9c2 incubadas com MTX e NAPHT, revelando que o fármaco e o seu metabolito 
podem alterar as vias celulares de forma distinta. 
 
Palavras-chave: Mitoxantrona; Naftoquinoxalina; Cardiotoxicidade; Células H9c2 
diferenciadas; Autofagia. 
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OUTLINE OF THE THESIS 
The present thesis consists of six sections. This thesis involves two main areas of 
research: the synthesis of a metabolite of mitoxantrone  (MTX), the naphthoquinoxaline 
(NAPHT), and the evaluation of the toxicity of MTX and its metabolite. 
 
1. INTRODUCTION  
In this section, a review on the existing literature on the cardiotoxic effects of 
anticancer drugs and the possible influence of metabolism on that cardiotoxicity is 
presented. 
 
2. AIMS 
Herein the main objectives of the present thesis are described.  
 
3. MATERIALS AND METHODS  
In this chapter, the experimental procedures are described. The synthesis and the 
methods used for the structural characterization of the synthesized compounds are detailed. 
Also, the protocols used to evaluate the toxicological profile of MTX and NAPHT are 
described. 
 
4. RESULTS  
Results were subdivided in two subsections. In the first part, the synthesis and 
structural determination of the two synthesized derivatives of MTX are presented. In the 
second part, the results of the in vitro toxicological evaluation of MTX and NAPHT are 
described. 
 
5. DISCUSSION AND CONCLUSIONS 
This chapter includes the discussion and the general conclusions of the developed 
work. 
 
6. REFERENCES 
In this final part, the scientific literature used in the remaining sections is listed. 
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1.1. The problem of cardiotoxicity caused by anticancer drugs 
Presently, cancer is one of the most concerning health issues worldwide. Over 3.45 
million new cases of cancer (excluding non-melanoma skin cancers) and 1.75 million deaths 
were registered in Europe in 2012, with breast and prostate cancers counting for more than 
800.000 new cases (Ferlay et al., 2013). Cancer is currently the second leading cause of 
death in Portugal, after cardiovascular diseases. The colorectal cancer is the leading cause 
of cancer-related mortality in Portugal (Adão et al., 2013).  
Briefly, cancer is a disequilibrium between cell division and cell death, accompanied 
with dysregulation of cell differentiation, which results in a limitless replicative potential and 
uncontrolled multiplication (Almeida et al., 2005, Ruddon, 2007). Most drugs used in cancer 
chemotherapy affect neoplastic transformation, cell proliferation, invasion and metastasis, 
and/or tumour-related angiogenesis. Ideally, targeted therapy spares normal cells and, 
therefore, would be better tolerated. The higher selectivity should translate into a wider 
therapeutic window that better enables the use of sufficient drug dosages to accomplish the 
therapeutic goals of tumour eradication or control, while minimizing the risk of resistance or 
toxicity (Bruce and Lin, 1969, Faivre et al., 2006). From the pharmacological point of view, 
agents used in anticancer therapy can be divided in chemotherapeutic agents (with several 
subgroups), biological or immunological agents. Radiation can also be used against cancer 
(Ewer and Suter, 2010). Chemotherapy is still the most frequent currently used therapy and 
it has largely contributed to the significant decrease of morbidity and mortality in several 
types of cancer. Even so, chemotherapy has general disadvantages, namely the potential 
development of cancer resistance and adverse effects due to the lack of selectivity of the 
drugs used (Espinosa and Raposo, 2010). Presently, the increase on the number of cancer 
survivors has led to the increase in toxic effects in non-target organs, especially long-term 
toxic effects. Several antineoplastic agents, namely cytotoxic antimetabolites, 
topoisomerase II inhibitors, alkylating and agents that interfere with tubulin, tyrosine kinase 
inhibitors, hormonal agents, and biological agents, among others, are widely reported to 
cause cardiac toxicity (Sá et al., 2009, Costa et al., 2013). The heart is an organ with limited 
potential for regeneration and, therefore, its damage may have long-term importance (Ewer 
and Suter, 2010). 
The cardiotoxicity resulting from antineoplastic therapy is a growing concern for 
oncologists and cardiologists. The cardiotoxicity resulting from the administration of 
anticancer drugs is multifactorial and complex, as it is influenced by factors as dose, 
possible drug interactions, potential synergism by co-administration or sequential 
1. Introduction 
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administration of chemotherapeutic cardiotoxic drugs or the application of other 
therapeutics with potential cardiac toxicity (for example: radiotherapy in the mediastinum or 
immunotherapy) (Table 1) (Ewer and Suter, 2010, Senkus and Jassem, 2011, Octavia et 
al., 2012). Moreover, the biological variability of the patient and its health in the moment of 
treatment and thereafter has also a significant impact on the cardiovascular effects of the 
chemotherapeutic agent/combination of agents to be used. Therefore, when an attempt is 
made to diagnose or predict future cardiovascular effects after chemotherapy or radiation 
therapy, a large number of variables must be taken into account (Colombo and Cardinale, 
2013).  
Several cardiotoxic manifestations can arise from xenobiotic exposure, namely 
damage in electrophysiology mechanisms, in the cardiac muscle and/or changes in the 
lumen diameter of coronary arteries. From the clinical perspective, the cardiotoxicity caused 
by anticancer agents is associated with temporary functional impairment, permanent loss 
of contractile elements, abnormalities of rhythm formation and/or conduction, as well as 
vascular effects that include vasospasms, alterations of blood pressure and 
thromboembolic sequelea (Senkus and Jassem, 2011). One of the most common 
cardiotoxic manifestations associated with the antineoplastic agents is the development of 
left ventricular dysfunction, namely decreased left ventricular ejection fraction (LVEF), which 
can progress to congestive heart failure. Heart failure is a severely debilitating disease that 
results, in a few years, on the death of the majority of the patients diagnosed (Colombo and 
Cardinale, 2013).  
The cardiac adverse effects of anticancer drugs may or may not be permanent. 
According to damage caused chemotherapy agents are divided in two groups: type I and 
type II (Table 1).  
The type I agents show cardiotoxicity associated with the total cumulative dose of 
the drug administered and a high propensity for cardiac cell death occurs after exposure 
(Ewer and Suter, 2010). Type I chemotherapy-related cardiac dysfunction, typically 
anthracycline-induced, is irreversible and typically associated with significant ultrastructural 
changes at biopsy (Todaro et al., 2013). Type II agents can cause a reversible cardiac 
dysfunction (Ewer and Suter, 2010). In fact, type II chemotherapy-related cardiac 
dysfunction (often termed trastuzumab-induced) is associated with reversible myocardial 
dysfunction rather than structural damage, it is highly reversible (up to 79%) and generally 
is not dose-related. However, a synergistic cardiotoxic effect between anthracyclines and 
trastuzumab has been demonstrated, especially when the two compounds are administered 
over a short period of time. Type II agents are not described as causing cell death; however, 
when used in combination with anthracyclines or other type I agents or in high-risk cardiac 
patients, some degree of cell death can actually occur (Todaro et al., 2013). 
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Table 1. Comparison of cardiotoxicity caused by agents of type I and type II. Table adapted 
from Ewer and Suter, 2010, Senkus and Jassem, 2011, and Adão et al., 2013. 
Type I (myocardial damage) 
example: Doxorubicin 
Type II (myocardial dysfunction) 
example: Trastuzumab 
Predominantly cell death Cellular dysfunction 
Biopsy changes: vacuoles, sarcomere/ 
myofibrillar disruption, apoptosis and necrosis 
No typical anthracycline-like biopsy changes: 
benign ultrastructure appearance 
Cumulative dose-related Not cumulative dose-related  
Permanent (myocyte death, bad prognosis) 
and irreversible cell damage; may stabilize, 
but subclinical damage persists 
Predominantly reversible (myocyte 
dysfunction, good prognosis), high probability 
of recovery after therapy interruption 
Risk factors: 
 Chemotherapy of combination prior or 
concomitant 
 Age  
 Previous cardiac disease 
 Hypertension 
Risk factors: 
 Chemotherapy prior or concomitant 
with anthracyclines or taxanes 
 Age  
 Previous cardiac disease 
 Obesity 
Mechanisms of cardiotoxicity: 
 Reactive oxygen species formation, 
oxidative stress/damage, energy 
collapse, and calcium and iron 
dysregulation 
Mechanisms of cardiotoxicity: 
 Block the human epidermal growth 
factor receptor 2 (HER2) signalling 
pathway, elimination of HER2/HER4-
related survival factors (gene 
expression, growth, glucose uptake, 
sarcomere turnover) 
Cardiovascular effects:  
 May result in heart failure and death 
Cardiovascular effects:  
 Low probability of cardiovascular 
mortality 
 
The best well-characterized cardiotoxic agents are the anthracyclines, namely 
doxorubicin (DOX), but other oncology drugs can also cause serious cardiovascular 
complications (Colombo and Cardinale, 2013). The anticancer drugs that adversely affect 
the cardiovascular system are systematized in Table 2. 
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Table 2. Agents used in anticancer therapy associated with cardiovascular toxicity. Table 
adapted from Ewer and Suter, 2010. 
(I) Agents associated with impaired left ventricular contractility 
(a) Agents associated with type I related cardiac dysfunctions  
(i) Anthracyclines: Doxorubicin, daunorubicin, epirubicin, 
idarubicin 
(ii) Anthraquinones: Mitoxantrone 
(b) Agents associated with type II related cardiac dysfunction (agents associated with 
potentially reversible dysfunction of the myocyte contractile elements) 
(i) Trastuzumab, lapatinib, sunitinib and others monoclonal antibodies/ tyrosine 
kinase inhibitors 
(c) Other cardiodepressant agents 
(i) Cyclophosphamide (especially high dose) 
(ii) α-Interferon 
(II) Agents associated with ischemia 
(a) 5-Fluorouracil 
(b) Capecitabine 
(c) Vinblastine 
(d) Vincristine 
(e) Bleomycin 
(f) Cisplatin 
(g) Biological response modifiers 
(III)  Agents associated with hypertension or hypotension 
(a) Bevacizumab 
(b) Sunitinib 
(c) Sorafenib 
(d) Homoharringtonine 
(e) Interleukin-2  
(IV) Miscellaneous cardiotoxic agents  
(a) Paclitaxel (bradycardia) 
(b) Arsenic trioxide (QT prolongation and torsades de points) 
(c) Radiation (pericardial damage, but may damage all cardiac structures)  
 
Several drugs have shown to cause toxicity towards the heart. Anthracyclines and 
mitoxantrone (MTX) have been widely described as cardiotoxic (Seiter, 2005, Menna et al., 
2008, Adão et al., 2013, Todaro et al., 2013). In the introduction of this thesis, anthracyclines 
[DOX and daunorubicin (DNR)], cyclophosphamide and MTX will be addressed for their 
cardiotoxicity in independent sections: anthracyclines for their frequent clinical use and the 
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wide literature available; cyclophosphamide whose cardiotoxicity and antineoplastic effects 
strongly relates to its metabolism; and MTX as it is the drug of study in the present 
dissertation. 
 
1.2. Anticancer drugs that lead to cardiotoxicity 
 
 Anthracyclines 
Anthracyclines and related compounds are intercalating agents that are effective in 
treating many malignant diseases. DOX and DNR belong to the anthracyclines group. This 
family of compounds share a similar chemical structure (Figure 1) (Monsuez et al., 2010, 
Menna et al., 2012). According to the World Health Organization, to the group of 
anthracyclines belong 17 essential drugs that are used to treat cancers (Sikora et al., 1999). 
The skeleton of anthracyclines is composed by a tetracyclic system with quinone and 
hydroquinone moieties (often named anthraquinone skeleton), an amino sugar 
(daunosamine) attached by a glycosidic bond to C-7, and a side chain with a carbonyl group 
at C-13 (Figure 1) (Menna et al., 2012). 
 
 
 
Compounds R1 R2 R3 R4 
DOX OH OCH3 OH H 
DNR H OCH3 OH H 
 
Figure 1. Chemical structure of DOX and DNR. 
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The anthracyclines were first isolated in the early 1950s from Streptomyces 
peucetius (Minotti et al., 2004a). During the decade of 1960, DNR was found to be very 
effective in treating leukaemia’s and lymphomas (Tan et al., 1967). Also in the sixties, a 
resembled molecule of DNR, the 14-hydroxydaunomycin or adriamycin (later named as 
DOX) was isolated and shown to be a more effective anticancer agent than DNR in solid 
tumours (Arcamone et al., 1969, Di Marco et al., 1969). Anthracyclines are shown to have 
a high therapeutic efficacy towards several types of cancers, although cardiotoxicity is one 
of their most significant adverse effects (Bonadonna et al., 1970). Over the years, the search 
for new compounds produced by the same bacteria led to the discovery of five new 
anthracyclines, however all still cardiotoxic (Takemura and Fujiwara, 2007). 
Anthracyclines are often used in combination with other antineoplastic agents, in the 
treatment of Hodgkin's disease, non-Hodgkin's lymphomas, acute leukaemia’s, bone and 
soft-tissue sarcoma, neuroblastoma, Wilm's tumour, and malignant neoplasms of the 
bladder, breast, lung, ovary, and stomach (Gewirtz, 1999, Minotti et al., 2004a). 
 
1.2.1.1. Pharmacological mechanisms and general adverse effects of 
anthracyclines  
Several mechanisms for the anticancer proprieties of anthracyclines have been 
suggested: they are deoxyribonucleic acid (DNA) intercalating agents and disruptors of 
topoisomerase II, they cause oxidative stress, show alkylating properties and/or cause 
direct effects on the cell membrane. Anthracyclines have also been reported as inhibitors 
of the helicase, DNA polymerase, besides topoisomerase II. They induce apoptosis as a 
result of topoisomerase II inhibition (Uchegbu et al., 1995, Gewirtz, 1999, Minotti et al., 
2004a, Takemura and Fujiwara, 2007, Ewer and Suter, 2010). Topoisomerase II is 
generally recognized to be the cellular main target of DOX. Anthracyclines act by stabilizing 
a reaction intermediate in which DNA strands are cut and covalently linked to this enzyme, 
therefore disrupting the DNA from returning to its natural structure (Simunek et al., 2009).  
Anthracyclines administration is accompanied by adverse drug reactions arising 
from their limited selectivity towards cancer cells (Aronson, 2006). Particularly common are 
bone marrow depression, which is dose-limiting, and gastrointestinal problems. Alopecia 
occurs in the majority of patients. Occasional hypersensitivity reactions may also occur. 
However, a cumulative-dose dependent cardiac toxicity has been the major limitation of 
DOX usage (Aronson, 2006). 
 
1.2.1.2. Cardiotoxicity of anthracyclines 
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Anthracyclines cardiotoxicity was not detected during the preclinical animal testing; 
however, it was described during the initial clinical trials with DNR and DOX (Bonadonna et 
al., 1970). Since then, the cardiotoxicity associated with anthracyclines has been intensively 
studied. Anthracyclines can cause acute, subacute and late cardiac damage. Acute 
morbidity occurs during or shortly after drug infusion and includes arrhythmias 
(supraventricular tachycardia, ventricular ectopy) accompanied in some patients by heart 
failure, pericarditis-myocarditis syndrome, as well as non-specific ST–T changes and QT 
prolongation (Senkus and Jassem, 2011). This acute toxicity is usually reversible and not 
dose-dependent. Acute cardiotoxicity occurs in 1% of patients and no development of 
chronic heart failure occurs later in life (Todaro et al., 2013). The subacute cardiac toxicity 
occurs within a few weeks, clinically resembles myocarditis (with oedema and thickening of 
the left ventricle walls), and is accompanied by diastolic dysfunction with a 60% mortality 
rate. These acute and subacute forms of cardiac morbidity are, however, rare (1-4%) 
(Senkus and Jassem, 2011). Anthracyclines can cause short-term adverse effects that may 
occur up to one year after the start of therapy, while the adverse long-term effects can be 
diagnosed years or decades after the end of anticancer therapy. In fact, clinically the most 
relevant side effect of anthracyclines is chronic cardiac toxicity leading to left ventricular 
dysfunction and most importantly congestive heart failure (Senkus and Jassem, 2011). 
Late-onset chronic left ventricular dysfunction occurs in 1.6–5% of patients at least 1 year 
to 10 to 30 years after completion of therapy. A study documented chronic left ventricular 
dysfunction later in life in 23% of children treated with anthracyclines (Todaro et al., 2013). 
A strong correlation between chronic left ventricular dysfunction and the cumulative dose of 
anthracyclines is widely demonstrated (Todaro et al., 2013). The prognosis in anthracycline-
related heart failure is poor, with 50% 2-year mortality in untreated established left 
ventricular dysfunction (Senkus and Jassem, 2011, Colombo and Cardinale, 2013). 
However, early diagnosis and appropriate management can significantly improve the 
outcome and the quality of life of the patients (Colombo and Cardinale, 2013).  
The risk factors for cardiac toxicity of anthracyclines are: the cumulative dose of the 
anthracycline administered, age, prior radiation therapy, concomitant (or previous) 
administration of other cardiotoxic anticancer agents and heart disease or pre-existing 
factors of cardiac risk (de Graaf et al., 1997, Pai and Nahata, 2000, Octavia et al., 2012, 
Adão et al., 2013) (Table 3). Clinical cases and pharmacovigilance data already obtained 
suggest that the most important risk factor for the development of delayed cardiotoxicity by 
anthracyclines is the maximum cumulative dose taken during all lifespan. After the absolute 
maximum cumulative dose threshold, the cardiotoxicity increases exponentially. This 
absolute cumulative dose varies according to the different anthracyclines (de Graaf et al., 
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1997, Pai and Nahata, 2000, Menna et al., 2008, Volkova et al., 2011, Geisberg et al., 2012, 
Adão et al., 2013) (Table 3).  
 
Table 3. Risk factors associated with the cardiotoxicity of anthracyclines. Table adapted 
from Ehninger et al., 1990, Mortensen et al., 1992, Singal and Iliskovic, 1998, Menna et al., 2008, 
Octavia et al., 2012, and Adão et al., 2013. 
Risk factors associated with cardiotoxicity of anthracyclines  
Risk factor Increased risk 
Age  
Paediatric patients or elderly to whom is 
administered the same cumulative dose 
Gender Female 
Method of administration Rapid intravenous injection 
Cumulative dose 
Most important predictor of cardiac dysfunction. 
Exceeding the cumulative dose of: 
Daunorubicin 550-800 mg/m2 
Doxorubicin 400-550 mg/m2 
Epirubicin 900-1000 mg/m2 
Idarubicin 150 - 225 mg/m2 
Mitoxantrone >100 - 140 mg/m2 
Chemotherapeutic combination 
Therapy with cyclophosphamide, 5-fluorouracil, 
taxanes or trastuzumab 
Mediastinal irradiation Previous or concurrent 
Previous cardiovascular disease Hypertension, coronary heart disease 
Electrolyte disturbances Hypocalcemia, hypomagnesemia 
 
The extremes of age, female gender, concomitant use of cyclophosphamide, 5-
fluorouracil, taxanes or trastuzumab, previous mediastinal irradiation, cardiovascular 
comorbidities and their predisposing factors (hypertension, coronary disease, and 
smoking), diabetes mellitus, liver disease and hyperthermia also increase the incidence of 
anthracyclines’ cardiotoxicity. The inter-individual variability regarding the susceptibility to 
cardiotoxicity observed after anthracyclines treatment is also attributed to genetic heritage 
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(de Graaf et al., 1997, Pai and Nahata, 2000, Octavia et al., 2012, Adão et al., 2013). 
Genetic factors possibly associated with sensitivity to anthracycline-induced cardiac 
damage include polymorphisms of multidrug resistance proteins 1 and 2, carbonyl 
reductase, 3 subunits of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
and phase II detoxification enzymes such as glutathione-S-transferase of the P family 
(Senkus and Jassem, 2011). 
Since this thesis main focus is cardiotoxicity and metabolism, the cardiotoxicity and 
pharmacokinetic aspects of anthracyclines will be briefly referred in the next sections. DOX 
will be detailed as the reference drug. Most of the general mechanisms of anthracyclines’ 
toxicity are similar to those of DOX in this group and will not be the primary objective of this 
thesis. For systematization purposes, DNR will only be addressed regarding metabolism 
and its effect on cardiotoxicity.  
  
1.2.1.3. General data on the pharmacokinetics of anthracyclines 
In general, DNR and DOX are administered intravenously and they suffer hepatic 
metabolism and biliary excretion. The clearance plasma curve of DOX and DNR is 
multiphasic, with a 30 hours (h) half-life. The anthracyclines quickly reach the heart, the 
kidneys, the lungs, the liver and the spleen (Twelves et al., 1998). The distribution of a drug 
within the body is governed by factors such as blood flow to different organs, diffusion, 
protein and tissue binding, and lipid solubility. In general, drugs with extensive binding to 
tissues (e.g., DOX) or with high lipid solubility tend to exhibit prolonged elimination phases 
because there is a slow release from the tissues (Patel et al., 2013).  
The metabolism of anthracyclines consists in several biochemical processes that 
vary according to the molecule. In general, the metabolic processes such as reduction of 
the C-13 carbonyl group (process more relevant in humans, accomplished by reductases 
of the aldo/ketoses or carbonyl reductases that gives rise to alcohols), the reductive 
cleavage of glycosidic C-7 and the hydrolytic cleavage of glycosidic ring are the most 
relevant (Menna et al., 2012). In Figure 2, the general metabolism of anthracyclines is 
presented.  
Anthracyclines can be reduced at C-13. In the reduction of the C-13 carbonyl, the 
NADPH-dependent aldo/ketoses reductases enzymes add two electrons to the C-13 side 
chain of the anthracycline. The metabolites formed are designated doxorubicinol in the case 
of DOX and daunorubicinol in the case of DNR (Bachur and Gee, 1971, Minotti et al., 1995). 
Doxorubicinol is more hydrophilic than DOX and accumulates within the cardiomyocytes 
(Costa et al., 2013). Another metabolic process very relevant to the anthracyclines 
cardiotoxicity occurs after the reduction processes of the quinone ring (Serrano et al., 1999). 
Other metabolic routes include glycosidic breakage bond therefore producing aglycones, 
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which may be demethylated and conjugated via sulfate or glucuronide routes (Di Marco et 
al., 1967, Alberts et al., 1971, Takanashi and Bachur, 1976, Uchegbu et al., 1995, Minotti 
et al., 2004a).   
 
 
 
Figure 2. The general metabolism of anthracyclines.  
 
 Doxorubicin 
DOX is the most widely used anticancer drug and the drug with the largest spectrum 
of anticancer action (Seiter, 2005). DOX is a cytotoxic antibiotic whose planar core 
intercalates with the DNA double helix and forms a ternary complex with topoisomerase II 
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and DNA. DOX also inhibits topoisomerase II directly, interacts with cellular and 
mitochondrial membranes, disturbs the transmission of intracellular signals and leads to the 
formation of reactive oxygen species (Gewirtz, 1999, Patel et al., 2013). Injectable DOX use 
is indicated for the treatment of various types of cancers and the doses used vary depending 
on the type of tumour. The most commonly used schedule is 60 to 75 mg/m2 every three 
weeks (Seiter, 2005). 
  
1.2.2.1. Cardiotoxicity of doxorubicin: human studies 
The most common side effects of DOX are bone marrow suppression, 
cardiomyopathy, electrocardiogram (ECG) changes, nausea, vomiting, diarrhoea, and 
alopecia (Eksborg et al., 1985, Octavia et al., 2012). In fact, despite the clinical usefulness 
of this drug, its use is limited due to its acute and chronic cardiotoxic effects (Volkova et al., 
2011). The primary factor limiting the use of DOX is the prolonged and cumulative exposure 
that typically results in the development of cardiomyopathies and, in more severe cases, 
congestive heart failure (Xu et al., 2005, Senkus and Jassem, 2011). In order to decrease 
the probability of cardiomyopathy development, it is recommended that the total cumulative 
dose of DOX should not exceed 450 mg/m2 to 550 mg/m2 of body surface area (Eksborg et 
al., 1985, Minotti et al., 1995, Singal and Iliskovic, 1998, Menna et al., 2008). Other risk 
factors for cardiotoxicity may lead to the recommendation to decrease its total cumulative 
dose (Table 3). 
One of the first studies performed on DOX cardiotoxicity was a retrospective analysis 
of over 4000 patients who received DOX done by Von Hoff et al. (Von Hoff et al., 1979). 
More than two per cent (2.2%) of patients developed clinical signs and symptoms of 
congestive heart failure (Von Hoff et al., 1979). This study was performed to demonstrate 
that a major determinant for the development of heart failure is the cumulative dose of DOX 
and that there was a marked increase in the prevalence of heart failure after a total 
cumulative dose of 550 mg/m2 (Von Hoff et al., 1979). However, the total dose of only 240 
or 250 mg/m2 of DOX can already cause pathological changes in the myocardium, as shown 
in subendocardial biopsies of DOX-treated patients (Billingham et al., 1978, Von Hoff et al., 
1979). Others studies focusing on LVEF determined that decreased LVEF is dependent on 
the cumulative dose, particularly in cumulative doses of DOX higher than 350 mg/m2 
(Alexander et al., 1979, Buzdar et al., 1985).  
In a more recent retrospective analysis of treatment with DOX for breast cancer or 
small cell lung cancer, LVEF was also measured (Swain et al., 2003). Swain et al. showed 
that 5.1% of patients had evidence of congestive heart failure or significant decrease in left 
ventricular function (Swain et al., 2003). This study also demonstrated an increased 
cardiotoxicity risk at a cumulative dose of DOX below 300 mg/m2 (Swain et al., 2003). Other 
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studies demonstrated nonspecific changes in electron microscopy, including decrease in 
myocardial myofibrils, mitochondrial defects, and cell degeneration caused by DOX 
(Chabner et al., 2012). Sequential echocardiograms detected structural abnormalities in 
25% of children who received up to 300 mg/m2 of DOX, although less than 10% showed 
clinical manifestations of cardiomyopathy on long-term monitoring (Chabner et al., 2012).  
Clinical incidence of apparent cardiomyopathy after DOX administration ranges from 
1 to 10% in total doses lower than 450 mg/m2. The risk rises sharply with dose and it is 
estimated heart failure in up to 20% in a cumulative dose of 550 mg/m2 (Table 3) (Chabner 
et al., 2012). As stated, the cardiotoxicity risk increases in the presence of other risk factors 
(Table 3) (Volkova et al., 2011, Geisberg et al., 2012, Octavia et al., 2012).  
 
1.2.2.2. Mechanisms involved in the cardiac toxicity of doxorubicin  
Cardiovascular diseases, and specifically heart failure, can occur as a consequence 
of cancer therapy. Despite decades of basic and clinical research, anthracyclines and 
radiation therapy continue to cause clinically significant heart failure (Geisberg et al., 2012).  
Several mechanisms are suggested to explain the cardiac toxicity caused by 
anthracyclines. The hypotheses more accepted are: oxidative stress caused by the redox 
cycle of the parent drug, the presence of cardiotoxic metabolites and changes in 
homeostasis of calcium and iron. The immunological aspects are also considered co-
responsible for the cardiac anthracyclines’ toxicity (Uchegbu et al., 1995, Volkova et al., 
2011, Octavia et al., 2012). Defects in mitochondrial integrity and subsequent deterioration 
of the energy cycle of the myocardium, changes in calcium currents in sarcoplasmic 
reticulum and mitochondria, changes in gene expression of myocytes, activation of the 
ubiquitin-proteasome system and induction of apoptosis, as well as innate immunity 
activation are also culprits of DOX-induced cardiotoxicity. However, so far there is no single 
mechanism that totally explains the cardiomyopathy caused by DOX (Shi et al., 2011b, 
Volkova et al., 2011, Octavia et al., 2012).  
 
1.2.2.1.1. Hypothesis of oxidative stress 
The DOX toxicity in cardiomyocytes is associated with the formation of reactive 
species, mainly as a result of the redox metabolism of the parent quinone (Figure 3). The 
level of DOX-induced oxidative stress is up to 10 times greater in the heart than in the other 
tissues (liver, kidney, spleen) (Lenzhofer et al., 1983, Doroshow and Davies, 1986, Siveski-
Iliskovic et al., 1995, Mukherjee et al., 2003), and therefore oxidative injury of the heart is a 
widely accepted theory for the DOX-induced cardiotoxicity. Anthracycline-induced cell 
death can be inhibited by antioxidants, both in vitro and in vivo (Geisberg et al., 2012) 
although controversial data exist (Costa et al., 2013). 
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Figure 3. Oxidative stress related mechanisms for DOX-induced cardiotoxicity. Adapted 
from Costa et al., 2013. (SOD: superoxide dismutase)  
 
DOX easily enters cells through passive diffusion and accumulates in the 
cardiomyocytes. Intracellularly, DOX accumulates in the mitochondria due to DOX high 
affinity towards cardiolipin. This anthracycline may become cardiotoxic after one-electron 
reductive activation (Doroshow et al., 1980, Costa et al., 2013). One electron reduction of 
the quinone moiety of DOX results in the formation of a semiquinone free radical, which 
regenerates back to the parent quinone by reducing molecular oxygen to superoxide anion 
radical (O2●−) (Doroshow and Davies, 1986, Serrano et al., 1999). The NADPH 
oxidoreductases [cytochrome P450 (CYP450) or -b5 reductases, mitochondrial 
nicotinamide adenine dinucleotide reduced form (NADH) dehydrogenase, xanthine 
dehydrogenase, and endothelial nitric oxide synthase (NOS) (reductase domain)] can be 
responsible for the reduction of DOX quinone in the heart (Costa et al., 2013). The O2●− is 
converted to hydrogen peroxide (H2O2) spontaneously or through the action of superoxide 
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dismutase (SOD). Hydrogen peroxide has a low toxic potential, being eliminated from the 
body by enzymatic antioxidant defence system (catalase and glutathione peroxidase). 
However, in the presence of the transition metals, especially iron, H2O2 and O2●- can 
generate the highly toxic ●OH. This process occurs during the Haber-Weiss reaction, which 
is actually quite slow. The presence of iron strongly catalyses the formation of ●OH, in a 
two-step process. In the first step, ferric ion (Fe3+) is reduced in to ferrous ion (Fe2+) by O2●-
. Ferrous ion then reacts with H2O2 (formed during DOX reduction) and results in in the 
formation of ●OH (Figure 4). Unlike H2O2 and superoxide anion radical, ●OH is extremely 
reactive and cannot be neutralized by antioxidant enzymes (Kotamraju et al., 2002, Minotti 
et al., 2004b, Halliwell and Gutteridge, 2007). 
Moreover, DOX can directly bind to iron and, in the presence of oxygen, it can cycle 
between the Fe2+ and Fe3+ states (Figure 4). The DOX-Fe3+ complex can be reduced to the 
DOX-Fe2+ complex in the presence of NADPH CYP450 reductase, glutathione, or cysteine. 
These reactions are accompanied by the formation of O2●- and the conversion of the 
anthracycline quinone moieties to the semiquinone free radical (Doroshow et al., 1980, 
Rajagopalan et al., 1988, Vasquez-Vivar et al., 1997, Sawyer et al., 1999, Xu et al., 2005, 
Takemura and Fujiwara, 2007).  
As stated, the oxidation of the semiquinone again to the quinone results in the 
formation of the superoxide radical anion. It is believed that this radical is the initiator of 
oxidative stress caused by DOX in the heart. The reactive oxygen species formed, in 
particular the ●OH, can begin the peroxidation process of unsaturated membrane lipids and 
cause cellular damage in the myocardium (Kotamraju et al., 2002, Minotti et al., 2004b). In 
addition, reactive oxygen species can seriously affect nucleic acids and proteins, 
particularly ion channels and ion transporters (Halliwell and Gutteridge, 2007). It has been 
reported that DOX decreases the levels of enzymatic antioxidant defences (vitamin C, SOD, 
glutathione, catalase) making the heart more susceptible to oxidative stress (Costa et al., 
2013).  
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Figure 4. Iron involvement on DOX cardiotoxicity. Adapted from Torres and Simic, 2012. 
 
Importantly, it was also found that NOS3 also contributes to cardiac dysfunction and 
injury observed after DOX administration of a single dose of 20 mg/kg, in a study using mice 
(Neilan et al., 2007). The results strongly suggest that DOX induces cardiac reactive 
species production via a NOS3-dependent mechanism. When NOS3 is deprived of L-
arginine or cofactors, superoxide can be generated from the oxygenase domain instead of 
●NO, and this uncoupling may be associated with dissociation of NOS3 dimers. An 
alternative mechanism by which DOX can induce NOS3 to generate superoxide radical 
anion involves the conversion of DOX by the NOS3 reductase domain to an unstable 
semiquinone intermediate, which in turn produces superoxide radical anion in the presence 
of oxygen (Neilan et al., 2007). 
 
1.2.2.3. Hypothesis of impairment of calcium homeostasis and cell death 
pathways by doxorubicin  
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An alternative hypothesis for the cardiotoxicity caused by DOX is the hypothesis of 
mitochondrial damage and changes on mitochondrial calcium concentration. The change in 
mitochondrial calcium is associated with reactive oxygen species production and dissipation 
of the mitochondrial membrane potential, which in turn may result in depletion of cellular 
adenosine triphosphate (ATP) (Zhou et al., 2001, Geisberg et al., 2012). This change in the 
transport of calcium leads to an irreversible decrease in storage ability and cell death, tissue 
damage, and consequently compromised cardiac contraction (Zhou et al., 2001). It is 
important to notice that the changes caused by the accumulation of reactive oxygen 
species, the alteration in calcium homeostasis and the mitochondrial damage observed are 
not isolated events, but can occur sequentially or simultaneously after DOX exposure 
(Kalyanaraman et al., 2002). Intracellular calcium is involved in the mechanisms of cell 
death. Usually, it is known that if exposed to low concentrations of anthracyclines, 
cardiomyocytes undergo apoptosis, whereas if exposed to high concentrations 
cardiomyocytes undergo necrosis (Doroshow et al., 1980, Rajagopalan et al., 1988, 
Vasquez-Vivar et al., 1997, Sawyer et al., 1999, Takemura and Fujiwara, 2007). When cell 
exposure to anthracyclines leads to apoptosis, one of the mediators of this process is the 
transcription factor and DNA damage sensor p53, accompanied with the activation of 
caspases (proteases) (Geisberg et al., 2012). However, ceramide, a lipid degradation 
product and the Fas receptor-ligand system have also been implicated in the damage 
caused by anthracyclines (Friesen et al., 1996).  
 
1.2.2.4. Damage caused by metabolites of doxorubicin 
There are reports that attribute anthracyclines cardiotoxicity not only to oxidative 
stress, but also to the damage caused by their metabolites, namely their secondary alcohols 
derivatives and aglycones.  
DOX is metabolized by aldo/ketoses reductases that convert DOX to a secondary 
alcohol, the doxorubicinol (Figure 3). Those carbonyl reductases are present in the cytosol 
of cardiac cells (Boucek et al., 1987, Minotti et al., 1998). Cytosolic fractions from human 
myocardium have NADPH-dependent aldo/ketoses reductases capable of adding two 
electrons to the C-13 carbonyl group of DOX (Minotti et al., 1995). The doxorubicinol formed 
after enzymatic catalysis accumulates in the cardiac tissue and it is eliminated more slowly 
from the heart than the original drug, DOX (Gambliel et al., 2002). Stewart et al. 
demonstrated that doxorubicinol levels are higher (60%) than the levels of DOX in samples 
of heart tissue obtained from autopsies of patients treated with the parent compound 
(Stewart et al., 1993). Moreover, doxorubicinol levels are positively related to the cumulative 
administered dose of DOX (Stewart et al., 1993), which was identified as the main risk factor 
for the development of chronic cardiotoxicity since the early studies (Minow and Gottlieb, 
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1975). Autopsy tissues were collected from 35 patients who had received DOX at any time 
ante-mortem (Stewart et al., 1993).  The major species found in human autopsy cardiac 
tissues were doxorubicinol (median concentration 92 ng/g, range 0 to 484 ng/g), and DOX 
(median 58 ng/g, range 0-1665 ng/g). Of the ten organs studied, heart ranked fifth regarding 
the median DOX concentration and ranked fourth regarding median doxorubicinol 
concentration. These results showed that heart accumulates large amounts of DOX and of 
its alcohol metabolite (Stewart et al., 1993).  
Behnia and Boroujerdi used phenobarbital as an inhibitor of aldo/ketoses reductases 
after which they used DOX at 10 mg/kg, intravenously. They demonstrated a decrease of 
doxorubicinol levels in vivo, as well as a reduction in cardiac damage as assessed by serum 
levels of creatine kinase in the rat, when phenobarbital was administered (Behnia and 
Boroujerdi, 1999). The correlation between secondary alcohols and cardiotoxicity has also 
been clearly shown by the use of transgenic animals. Mice with only one functional copy of 
the gene carbonyl reductase are healthy and grossly normal despite having decreased 
levels of carbonyl reductase transcript and protein (Olson et al., 2003). To control wild-type 
animals and to carbonyl reductase transgenic mice were administered DOX at 20 mg/kg 
intraperitoneally. Within 2 weeks, 91% of wild-type mice were severely affected by DOX 
when compared to 18% of mice with only one functional copy of the gene carbonyl 
reductase. Transgenic mice showed decreased circulating levels of the metabolite, 
doxorubicinol, after administration. Echocardiography and histological analysis showed that 
those transgenic mice were protected from gross and cellular level pathologies associated 
with DOX treatment (Olson et al., 2003). Another study with transgenic mice that 
overexpressed a heart-specific human carbonyl reductase was performed (Forrest et al., 
2000); it was found that the administration of a single injection of DOX (15 mg/kg) in these 
animals resulted in a higher cardiotoxicity than in control wild-type mice (Forrest et al., 
2000). Moreover, levels of doxorubicinol were found to be four times higher in the human 
carbonyl reductase expresser hearts than in the nonexpressers. Acute cardiotoxicity was 
evident by a 60% increase in serum creatine kinase activity and a 5-fold increase in cardiac 
damage seen in the transgenic mice measured by electron microscopy. The human 
carbonyl reductase expressers survived for 5 weeks when compared with 12 weeks for the 
controls DOX-treated animals. Electrocardiograph profiles and necropsies showed the 
cause of death to be the development of cardiomyopathies leading to congestive heart 
failure. Electron microscopy data showed swelling and major structural damage of the 
mitochondria in the human carbonyl reductase expresser’s mice that had DOX treatment 
(Forrest et al., 2000). 
Doxorubicinol plays an important role in DOX cardiotoxicity, possibly by amplifying 
the damage induced by other species (e.g., reactive oxygen species). Thus, abnormal 
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increases of doxorubicinol formation in the heart can lead to an acceleration in the 
progression of cardiotoxicity and cause the development of heart failure at lower cumulative 
doses of DOX than predicted (Minotti et al., 2004a). Doxorubicinol is an inhibitor of cardiac 
contractility, acts on the calcium transport ATPase of the sarcoplasmic reticulum and in the 
calcium release promoted by the calcium channel of the sarcoplasmic reticulum (Olson et 
al., 1988). In preparations obtained from cardiac tissue, doxorubicinol is a negative inotropic 
agent even more potent than DOX (Olson et al., 1988). It should be added that doxorubicinol 
interferes with ferritin (Minotti et al., 1995). Doxorubicinol is able to release Fe2+ from ferritin, 
which is the major site of iron storage in cytosolic medium of human cardiomyocytes (Minotti 
et al., 1995, Minotti et al., 1996). Another work suggested that this secondary alcohol may 
also contribute to the cardiotoxicity through its ability to impair the iron regulatory protein/ 
aconitase system involved in the homeostasis of the intracellular iron (Minotti et al., 1998). 
Changes in iron homeostasis have been implicated in the cardiotoxicity induced by the 
DOX. Moreover, doxorubicinol or reactive oxygen species may contribute to cardiotoxicity 
by inactivating iron regulatory proteins that modulate the fate of the messenger ribonucleic 
acid (RNA) for the transferrin receptor and ferritin (Minotti et al., 2001). Doxorubicinol is also 
able to remove iron from the catalytic Fe-S cluster of cytoplasmic aconitase (Minotti et al., 
2001).  
The comparison between the properties of DOX and doxorubicinol has shown how 
a simple hydroxylation can strongly affect the toxic properties of those compounds (Heibein 
et al., 2012). Generally, doxorubicinol is less prone than DOX to cause oxidative stress. 
However, since it has a high cardiac accumulation (Stewart et al., 1993), doxorubicinol can 
lead to a large accumulation in the cardiac tissue when compared to the parent drug (Platel 
et al., 2000).  
DOX and doxorubicinol may still undergo reduction via the reaction of glucosidase 
generating metabolites called aglycones (Boucek et al., 1987) (Figure 5). The 
deglycosylation of the daunosamine sugar at C-7 aglycone of DOX may lead to 7-
hydroxydoxorubicin aglycone and 7-hydroxydoxorubicinol aglycone (Figure 5). The 
resulting hydroxyl group at C-7 can be metabolized to obtain 7-deoxydoxorubicin aglycone 
or 7-deoxydoxorubicinol aglycone (Takanashi and Bachur, 1976). 
47 
 
 
Figure 5. Doxorubicin formation of aglycones.  
 
Aglycones are powerful mitochondrial toxins and mitochondrial dysfunction further 
amplifies oxidative stress (Costa et al., 2013). The aglycones formed lead to increased 
permeability of the inner membrane in the mitochondria of the heart, being this phenomenon 
accompanied by the release of mitochondrial calcium, by mitochondrial swelling, disfunction 
of the membrane potential, and mitochondrial oxidation of pyridine nucleotides (Sokolove, 
1988). Aglycones can also modify mitochondrial sulfhydryl groups and induce a calcium 
independent oxidation of mitochondrial NADPH, which appears to redirect electron 
transport from NADH to oxygen and result in the production of superoxide radical anion 
(Sokolove, 1994). Calcium release and sulfhydryl modification are shown to depend 
similarly on aglycone concentration and on the C-7 substituent of the anthracycline ring 
(Sokolove, 1988). In particular, the 7-hydroxydoxorubicin aglycone decreased the amount 
of calcium required to trigger the mitochondrial permeability increase. 7-Deoxydoxorubicin 
aglycone, the most prominent aglycone metabolite of DOX, was similarly effective in 
inducing calcium release, and both aglycones were substantially more effective than the 
parent drug (Sokolove and Shinaberry, 1988). Sulfhydryl modification induced in 
mitochondria by 7-deoxydoxorubicin aglycone is more efficient than by 7-
hydroxydoxorubicin aglycone. High potency of aglycones towards thiols may reflect 
increased access to key membrane thiols, due to their enhanced hydrophobicity (Sokolove, 
1988). Moreover, Sokolove et al. examined the effects of DOX and its aglycone derivatives 
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on the pyridine nucleotide redox status of isolated, intact heart mitochondria. DOX 
aglycones induced the slow, calcium-independent oxidation of mitochondrial NADPH with 
7-deoxydoxorubicin aglycone showing greater or equal potency than 7-hydroxydoxorubicin 
aglycone. That ability was much greater than DOX (Sokolove, 1991).  
Studies on laboratory animals have limited value in the prediction of the structure 
and reactivity of toxic metabolites in humans. Therefore, some authors use ethically 
cytosolic fractions of myocardial samples obtained during surgery for coronary bypass 
grafting (Licata et al., 2000). After reconstitution with NADPH and incubation with DOX, 
these fractions generate the alcohol metabolite doxorubicinol as well as 7-deoxydoxorubicin 
aglycone and 7-hydroxydoxorubicinol aglycone. These data show that the reduction of the 
side chain carbonyl group, reductase-type deglycosylation of the anthracycline, and the 
hydrolase-type deglycosylation followed by carbonyl reduction, respectively, occurs in 
human samples. The authors have suggested through structure-activity considerations that 
aglycones and doxorubicinol may inflict cardiac damage by inducing oxidative stress and 
by perturbing iron homeostasis, respectively (Figure 5) (Licata et al., 2000).  
 
1.2.2.5. Hypothesis associated with immune and genetic mechanisms 
It was suggested by some authors that the cardiac damage caused by 
anthracyclines would increase due to their ability to activate the immune response. The 
damage caused by DOX in the cytoplasmic membrane of cardiomyocytes alone would 
compromise cardiac function, but the involvement of the immune system, with the 
consequent inflammatory response, exacerbates the cardiac dysfunction (Zhang et al., 
1993). Zhang et al. showed that there was evidence of inflammatory responses in mice 
treated with DOX, since they exhibited increased dendritic antigen presenting cells. These 
results indicated that DOX treatment triggers immune reactions in which interstitial dendritic 
cells function as the antigen-presenting cells of the heart (Zhang et al., 1993). In addition to 
this inflammatory response, the release of vasoactive amines (histamine, catecholamines, 
prostaglandins, etc), after DOX administration, causes chemotaxis, further aggravating 
cardiac dysfunction (Huber, 1990, Zhang et al., 1993).  
Another accepted mechanism for anthracyclines toxicity results from altered 
expression of cardiac proteins or the activation of some genetic programs. DOX negatively 
influences the expression of genes involved in the production of constitutive proteins of the 
cardiac muscle (cardiac troponin, myosin, etc) and mitochondrial proteins and other proteins 
(Takemura and Fujiwara, 2007), thus affecting the quality of cardiac work. Several 
transcription factors, including factor nuclear kappa B, are sensitive to the redox state of the 
myocyte (Valen et al., 2001) and redox mechanisms may explain, at least in part, the effect 
on the expression of this gene induced by DOX. 
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 Daunorubicin and its’ general pharmacokinetic data 
DNR was the first discovered active substance in the anthracyclines group (Iwamoto 
et al., 1968). This drug is for injectable use and has significant activity on acute 
myelogenous leukaemia, being rarely used in other types of tumours. DNR is also used in 
the treatment of neuroblastomas (Infarmed, 2011). DNR and DOX differ only in a hydroxyl 
group (Figure 1); however, their activity spectrum greatly differs (Infarmed, 2011). 
The recommended administration schedule for DNR is 25 to 45 mg/m2 for three 
days. Total doses higher than 550 mg/m2 are associated with a high cardiotoxicity risk 
(Table 3) (Chabner et al., 2012). DNR is widely distributed among tissues, mainly spleen, 
kidneys, liver, lungs, and heart (Trillet et al., 1985).  
DNR undergoes rapid and extensive metabolism in the liver and other tissues, 
mainly through cytoplasmic aldo/ketoses reductases. One hour after its administration, the 
predominant metabolite in the plasma is the metabolite daunorubicinol (Bachur and Gee, 
1971) that has a plasma half-life of 26.7h and has antineoplasic activity (Takanashi and 
Bachur, 1975, Roche, 2002).  
Other metabolic routes for DNR include the glycosidic bond breakdown resulting in 
the production of aglycones, which have little or no antiproliferative activity and are further 
demethylated and conjugated via sulfate or glucuronide (Figure 6) (Di Marco et al., 1967, 
Alberts et al., 1971). In mouse and rabbit hepatocytes in suspension, DNR was shown to 
be metabolized mainly into daunorubicinol and deoxydaunorubicinol aglycones. The 
deoxydaunorubicin aglycone was rarely observed in both species. The anthracyclines 
conjugates were not observed in hepatocytes of any species (Gewirtz and Yanovich, 1986).  
The overall metabolites of DNR were identified as: daunorubicinol, daunorubicinol 
aglycone, deoxydaunorubicin aglycone, deoxydaunorubicinol aglycone, demethyl 
deoxydaunorubicinol aglycone, deoxydaunorubicinol aglycone 13-O-β-glucuronide, 
demethyl deoxydaunorubicinol aglycone 4-O-sulfate and demethyl deoxydaunorubicinol 
aglycone 4-O-β-glucuronide. The human DNR metabolism involves mainly reduction of the 
carbonyl, reductive glycosidic cleavage, O-demethylation, O-sulfation and O-
glucuronidation (Figure 6) (Takanashi and Bachur, 1975). 
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Figure 6. Main metabolites of DNR. 
 
DNR and its metabolites are excreted in urine and bile (approximately 40% of the 
administered dose) (Rusconi et al., 1968, Alberts et al., 1971).  
 
1.2.3.1. Cardiotoxicity of daunorubicin and daunorubicinol 
The risk of developing congestive heart failure increases even in the absence of 
other cardiac risk factors when the total cumulative dose of DNR exceeds 550-800 mg/m2 
in adults (Adão et al., 2013), 300 mg/m2 in children over two years of age, or 10 mg/kg in 
children under two years of age (Mortensen et al., 1992). These cardiotoxicity effects are 
long known (Bonadonna and Monfardini, 1969, Marmont et al., 1969) and the risk factors 
for cardiotoxicity resemble other anthracyclines (Table 3). 
Several studies were performed in animal models to better highlight the 
cardiotoxicity of DNR and its main metabolite, daunorubicinol. In a rat model, and after 
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treatment with 6 doses 3 mg/kg intraperitoneally, DNR showed a strong ability of decreasing 
functional cardiac parameters, while daunorubicinol administered in the same dose and 
administration route did not cause any observed cardiotoxicity (Platel et al., 2001). Both 
treatments led to a similar accumulation of daunorubicinol in the myocardium while DNR 
was found only in the hearts of rats treated with this drug and not with daunorubicinol (Platel 
et al., 2001). Direct infusion to isolated rat hearts of the same dose (10 µM) of DNR or 
daunorubicinol induced a depression of heart function in both groups; however, only DNR 
induced a progressive increase in diastolic pressure. On the other hand, in cardiac 
sarcoplasmic reticulum vesicles, daunorubicinol at a concentration of 5.5 µ/g tissue or 10 
µM inhibited calcium uptake by 39 ± 3%, whereas 10 µM of DNR did not cause any 
detectable inhibition (Cusack et al., 1993). Another study, however, demonstrated that both 
DNR and daunorubicinol were several fold more potent at inhibiting than they were at 
stimulating sarcoplasmic reticulum calcium release in canine heart vesicles (Olson et al., 
2000). Concentrations that cause 50% inhibitory effect (IC50) on caffeine-induced calcium 
release of DNR and daunorubicinol were 1.2 and 0.6 µM, respectively, and for spontaneous 
calcium release were 3 and 1 µM, respectively (Olson et al., 2000). The model used and 
the amounts of calcium used for loading may explain these dissimilar results. After DNR or 
daunorubicinol administration with 6 doses of 3 mg/kg intraperitoneally on rat, DNR strongly 
decreased the cardiac functional parameters, while daunorubicinol did not induce 
cardiotoxicity (Platel et al., 2001).  
In summary, DNR follows the same metabolic route of DOX, namely regarding the 
reduction to daunorubicinol (Loveless et al., 1978). However, in contrast to DOX, DNR 
administration leads to much higher concentrations of this metabolite in the plasma and 
tissues than the parent compound (Robert and Gianni, 1993, Platel et al., 2001), whereas 
the formed alcohol metabolite is less cardiotoxic than the initial drug (Platel et al., 2001). 
 
1.3. Alkylating agents (i.e. cyclophosphamide) and their cardiotoxicity 
Alkylating agents are highly reactive compounds that readily bind to phosphates, 
amines, imidazole and hydroxyl groups found in nucleic acids. The cytotoxic and mutagenic 
effects of alkylating agents are directly related to DNA alkylation, which can lead to the 
replacement of base pairs, breaks or the formation of covalent bonds between DNA strands, 
stopping the DNA replication and causing cell death (Chabner et al., 2012). The most 
important pharmacological actions of the alkylating agents affect DNA synthesis and cell 
division. Therefore, they are more cytotoxic in rapidly proliferating tissues. However, these 
agents affect both healthy and cancer cells and notwithstanding act on the cells at any stage 
of the cycle (Chabner et al., 2012). Cyclophosphamide is an alkylating agent used orally or 
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by intravenous administration. It prevents cell proliferation and acts mainly in malignant 
cells, therefore being used for treating various types of cancer, including colon-rectal, breast 
and their metastases, adenocarcinoma of the lung, testicle, prostate, endometrial, ovarian, 
bladder, or kidney cancers, soft tissue sarcoma, acute lymphocytic leukaemia, myelocytic 
and monocytic leukaemia, multiple myeloma, Wilms' tumour, Hodgkin’s disease, non-
Hodgkin’s lymphoma, Burkitt's lymphoma, as well as disorders of the autoimmune system, 
Wegener's granulomatosis, myasthenia gravis, multiple sclerosis, hemolytic anaemia, and 
other conditions (Infarmed, 2004). It has been used as an immunosuppressant for the 
prevention of transplant rejection in kidney, liver, heart, bone marrow, but it has been also 
used in rheumatoid arthritis, systemic lupus erythematosus, and nephrotic syndrome 
(Goldberg et al., 1986, Infarmed, 2004). It is a prodrug, therefore it requires a process of 
metabolic activation, mainly by CYP450 (in the liver and tissues) before exercising its 
anticancer actions (Figure 7). 
Regarding to pharmacokinetics, cyclophosphamide is well absorbed orally, with an 
oral bioavailability of 75%. The peak plasma level occurs one hour after oral administration. 
The protein binding rate is relatively low (10% to 56%), while the volume of distribution is 
0.48 to 0.71 L/ kg. The elimination half-life is 1.3 to 16h (Infarmed, 2004). 
Cyclophosphamide is less than 10% excreted in the urine as an unchanged drug and is 
85% to 90% excreted as metabolites (Infarmed, 2004). 
High therapeutic doses of cyclophosphamide may cause lethal cardiotoxicity. A 
combination of symptoms and signs of myopericarditis can result in congestive heart failure, 
arrhythmias, cardiac tamponade, and myocardial depression (Gottdiener et al., 1981, Ayash 
et al., 1992). Severe cardiac haemorrhagic necrosis has been reported in the high doses of 
cyclophosphamide used prior to bone marrow transplantation. The pathological findings in 
autopsy of patients treated with high dose cyclophosphamide and heart problems include 
dilated heart, transmural irregular bleeding, focal areas of fibrous pericarditis, myocardial 
necrosis and interstitial lesions with signs of haemorrhage, oedema and fibrin deposition 
(Crossley, 1984). In bone marrow transplantation, cyclophosphamide dosing can reach 
120-240 mg/kg provided for one to four days (O'Connell and Berenbaum, 1974, Appelbaum 
et al., 1976, Goldberg et al., 1986). The incidence of fatal cardiomyopathy varies from 2.0% 
to 17.0%, depending on the different regimens and populations. The large increases in 
plasma lactate dehydrogenase (LDH) and creatine phosphokinase suggest myocardial 
damage and their values are elevated in approximately half of the patients administered 
with high doses of this drug. Symptoms of cardiac necrosis may become apparent within 
two weeks after the administration, but are rapidly fatal when detected (Slavin et al., 1975).  
In the work of Goldberg and co-workers with patients that had not received any 
previous cardiotoxic therapy, namely anthracycline or radiation, the incidence of congestive 
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heart failure was reported to be 0/32 in patients receiving doses lower than 1.55 g/m2 and 
6/52 in patients receiving higher than 1.55 g/m2 cyclophosphamide (Goldberg et al., 1986). 
Reversible decreases in ECG voltage and increases in left ventricular mass, possibly 
reflecting myocardial oedema or haemorrhage were observed in the twice-daily, higher-
dose (mean total 174 ± 34 mg/kg) of cyclophosphamide regimen (Goldberg et al., 1986). 
Another study reported an incidence of 9% fatal cardiomyopathy and/or pericarditis with 
combination therapy or high-dose cyclophosphamide and total body irradiation (Cazin et 
al., 1986). The majority of patients in these studies had previously received anthracyclines, 
which certainly increased the risk of cardiotoxicity. In another study, the cardiotoxicity of 
cyclophosphamide administered twice daily at a high dose (total of 174 average ± 34 mg/kg) 
was evaluated and compared with a lower daily dose schedule (87 ± 11 mg/kg) (Braverman 
et al., 1991). The LVEF did not change significantly in both groups, however, four of the five 
patients who developed clinical cardiotoxicity belonged to the group with the highest dose 
(Braverman et al., 1991). 
Several therapeutic and toxic effects of cyclophosphamide seem to require its 
metabolic activation by hepatic microsomal CYP450 mixed function oxidase system and 
those metabolites were shown in vitro and in vivo to cause cardiotoxicity (Levine et al., 1993, 
Dorr and Lagel, 1994, Ismahil et al., 2011). Cyclophosphamide is extensively metabolized 
in the liver by CYP450 enzymes to active/toxic metabolites (4-hydroxycyclophosphamide, 
aldophosphamide, phosphoramide mustard, and acrolein) and inactive metabolites (4-
ketocyclophosphamide, carboxyphosphamide) (Figure 7) (Dorr and Lagel, 1994). The 
distribution of these metabolites can cause high cardiac concentrations of these 
metabolites, without need of in loco metabolization (Dorr and Lagel, 1994).  
Nakamura et al. investigated the toxic effects of cyclophosphamide, acrolein, and 
DOX in H9c2 cell line and in isolated rat hearts. Cyclophosphamide itself had no toxic effect, 
while the toxicity of acrolein was 1000 times greater than of DOX in cell line H9c2 
(Nakamura et al., 2010). In the isolated rat heart, acrolein, but not cyclophosphamide, 
reduced left ventricular pressure and heart rate and increased left ventricular end-diastolic 
pressure. These results suggest that the cardiac toxicity of cyclophosphamide may be 
caused by acrolein, one of its metabolites (Nakamura et al., 2010). 
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Figure 7. The main metabolites of cyclophosphamide (ALDH1: aldehyde dehydrogenase 
type 1). 
 
The conversion of the synthetic probe 4-hydroperoxyclophosphamide to the 
metabolite 4-hydroxycyclophosphamide and then its transformation to acrolein is rapid in 
vitro (Dorr and Lagel, 1994). The 4-hydroperoxyclophosphamide causes changes in the 
contents of various ions (Na+, K+, and Ca2+) and decreases the content of ATP in cardiac 
myocytes, all early indicators of cytotoxicity (Levine et al., 1993).  
Neonatal rat heart myocytes were used to evaluate the acute cardiotoxic effects of 
cyclophosphamide metabolites (Dorr and Lagel, 1994). The decrease in ATP levels on the 
myocytes with 4-hydroperoxycyclophosphamide and acrolein had an IC50 value of 123 µM 
and 152 µM, respectively. The parent compound, cyclophosphamide, had no significant 
action on ATP levels. Glutathione levels were initially reduced and then transiently elevated 
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following exposure to 4-hydroperoxycyclophosphamide (Dorr and Lagel, 1994). With 
acrolein, glutathione levels were reduced to non-measurable levels at all-time points 
evaluated (up to 72h). Finally, two exogenous sulfhydryl-containing compounds (mesna and 
N-acetyl cysteine) were shown to block the toxic effects of both 4-
hydroperoxycyclophosphamide and acrolein in that model. These results suggest that 
acrolein and 4-hydroperoxycyclophosphamide are equipotent cytotoxics and that a 
transient depletion in glutathione accompanies their toxic effects in cardiac myocytes (Dorr 
and Lagel, 1994, Nakamura et al., 2010).  
The intracellular antioxidant, glutathione, is suggested to play an important role in 
the protection against heart damage caused by cyclophosphamide (Friedman et al., 1990, 
Todorova et al., 2009), suggesting that the cardiac toxicity of cyclophosphamide involves 
oxidative stress and reactive metabolites. In Fischer 344 rats, administration of 
cyclophosphamide at a dose that is lethal to 10% of control athymic nude mice resulted in 
sudden death within 3h of the all mice that had been pre-treated with the glutathione 
synthesis inhibitor, buthionine sulphoximine. Cardiac monitoring revealed ventricular 
fibrillation to be the cause of death of those animals (Friedman et al., 1990). Adult mice 
cardiomyocytes exposed to 1 μM of acrolein showed a marked increase in the intracellular 
reactive oxygen species and calcium concentration, by 12- and 2-fold, respectively, 
compared to control values, corroborating the involvement of oxidative stress (Wang et al., 
2011). Acrolein (1 mg/kg daily) was administered orally to C57BL/6 mice by gavage-fed for 
48 days (Ismahil et al., 2011). Acrolein-fed mice exhibited significant left ventricular 
dilatation, contractile dysfunction, and impaired relaxation. Histological and biochemical 
evaluation revealed myocardial oxidative stress (membrane-localized protein-4-hydroxy-
trans-2-nonenal adducts), nitrative stress (increased protein-nitrotyrosine) and varying 
degrees of plasma and myocardial protein-acrolein adduct formation. These data showed 
physical translocation of the ingested acrolein to the heart. Acrolein also caused myocyte 
hypertrophy, increased apoptosis, and decreased cardiac activity of NOS3 (Ismahil et al., 
2011).  
Risk factors for the development of congestive heart failure caused by 
cyclophosphamide were already reported and include: cyclophosphamide doses of 
approximately 1.55 g/m2/day (Goldberg et al., 1986), administration of doses over 6h, 
instead of 30 to 60 minutes (min) (Kushner and Cheung, 1991), activation of 
cyclophosphamide and increased formation of metabolites (Ayash et al., 1992) and low 
levels of cardiac glutathione (Friedman et al., 1990). In fact, cyclophosphamide’s cardiac 
toxicity is undoubtedly related to levels of the antioxidant glutathione, and this antioxidant 
is present at low levels in the heart (Costa et al., 2013). The cyclophosphamide metabolites 
contribute to its cardiac toxicity, possibly through oxidative stress mechanisms. 
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1.4. Mitoxantrone 
MTX, 11,4-dihydroxy-5,8-bis[(2-[(2-hydroxyethyl)amino]ethyl)amino]-9,10-anthra-
cenedione (Figure 8) is an antineoplastic agent belonging to the family of the synthetic 
anthracenediones (Ehninger et al., 1990). MTX was originally synthesized in 1979 (Fox, 
2004). The main chemical alteration of MTX comparing with anthracyclines was the 
replacement of the amino sugar on the anthracyclines for aminoalkylalcohol chains (Figure 
8) (Pratt et al., 1986). 
 
 
 
Figure 8. The chemical structure of MTX. 
 
In 1979, Murdock published a work, which indicated that MTX had a potent 
anticancer activity (Murdock et al., 1979). MTX is the only compound in the series of 
anthracenediones that has undergone extensive clinical trials. MTX showed cytostatic 
effects both in vitro and in animal testing (Johnson et al., 1979, Schabel et al., 1983). In 
fact, in 1979, the phase I clinical trials with MTX were initiated to define the maximum 
tolerable doses with various administration regimens. MTX approval was aimed to maintain 
or improve the anthracyclines antitumor activity and reduce their cardiotoxic side effects 
(Fox, 2004, Ferlay et al., 2013).    
 
 Pharmacological mechanisms of mitoxantrone  
In clinical studies, the anticancer activity of MTX has been demonstrated in patients 
with advanced breast cancer, acute leukaemia and lymphoma, solid tumours and prostate 
cancer (Coltman et al., 1983, Paciucci et al., 1983, Smith, 1983, Yap et al., 1983, Stuart-
Harris et al., 1984, Seiter, 2005, Patel et al., 2013). In 2000, MTX was also approved by the 
U.S. Food and Drug Administration as an immunomodulation agent for reducing 
neurological disability of worsening relapsing-remitting or secondary progressive multiple 
sclerosis, an autoimmune disease characterized by the progressive destruction of the 
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myelin sheath surrounding axons in the central nervous system (Avasarala et al., 2003, 
Seiter, 2005, Neuhaus et al., 2006, Paul et al., 2009, Patel et al., 2013).  
The known mechanism of action of MTX involves the intercalation of DNA and 
inhibition of topoisomerase II activity (Ehninger et al., 1990, Seiter, 2005, Patel et al., 2013). 
Although the MTX chemical core contains a planar structure that is usually associated with 
intercalation of DNA, the extensive amino alkyl side chains in positions one and four prevent 
the incorporation of the entire molecule in the DNA helix (Neidle, 1978) (Figure 8). MTX 
binds to DNA through a mechanism that involves both hydrogen interactions, as well as -
 stacking (Lown et al., 1985). Some authors have demonstrated that MTX inhibits the 
synthesis of DNA, RNA and protein in vitro (Durr et al., 1983, Johnson et al., 1983). It is 
believed that the anticancer activity of MTX is due to the stabilization of topoisomerase II 
with a DNA cleavable complex (Liu, 1989). Cells treated with MTX exhibit typical cellular 
effects of topoisomerase II inhibitors, including inhibition of DNA synthesis, cell cycle arrest 
in the G2 phase and the occurrence of various types of breaks in the DNA chain (Bowden 
et al., 1985, Fox and Smith, 1990). MTX, at high concentrations, inhibits the biosynthesis of 
prostaglandins and the release of calcium, a finding that may have an additional meaning 
given the role of prostaglandins in metastatic spread of tumours and the hypercalcemia that 
occurs in cancers (Novak et al., 1988, Ehninger et al., 1990). Recently, the MTX potential 
epigenetic effects were demonstrated given its high affinity to bind to histone H1 and core 
histones in vitro (Hajihassan and Rabbani-Chadegani, 2011). Immunomodulatory effects of 
MTX may also contribute to its anticancer activity and its use in multiple sclerosis (Fidler et 
al., 1986). 
There are many studies that evaluate the reductive bioactivation of anticancer drugs 
by cellular oxidoreductases, especially by NADPH cytochrome reductase. These 
bioactivations can result in covalent DNA-binding of the formed metabolites (Cummings et 
al., 1991, Skladanowski and Konopa, 1994, Bailey et al., 2001), leading to a significant 
increase cytotoxic activity of these compounds (Bartoszek and Wolf, 1992, Patterson et al., 
1995, Cowen et al., 2003). The formation of reactive species is occasionally referred as a 
possible anticancer mechanism of MTX. However, while the reactive species can be 
generated in cells treated with MTX, a redox cycle quinone-dependent similar to DOX does 
not occur in biological conditions (Kharasch and Novak, 1983, Sinha et al., 1983, Duthie 
and Grant, 1989, Nguyen and Gutierrez, 1990). This subject will be addressed in the 
following sections. 
 
 Pharmacokinetics and metabolism of mitoxantrone 
MTX is poorly absorbed orally, so it is administered intravenously, intraperitoneally, 
or via intra-arterial administration through a continuous infusion (Ehninger et al., 1990). In 
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clinical studies using a single intravenous infusion of MTX, the administered dose ranges 
between 5-14 mg/m2, while the administration schedule can vary according to the disease 
and response to therapy, ranging from 4-6 weeks for the treatment of acute myeloid 
leukaemia, 3 weeks for the treatment of prostate cancer (Fox, 2004), and 3 months for 
multiple sclerosis (Scott and Figgitt, 2004). 
The plasma concentration-time curve of MTX can be best fitted with three 
exponentials: a rapid half-life of 4.1 to 10.7 min, corresponding to the moment when MTX 
rapidly leaves the plasma and binds to the endothelial surface; an intermediate half-life of 
0.3 to 3.1h, corresponding to the distribution phase; and a long terminal half-life of 8.9h to 
9 days (Batra et al., 1986, Ehninger et al., 1990, Fox, 2004). Therefore, MTX exhibits a 
rapid initial distribution phase followed by a relatively slow elimination phase from the deep 
tissues (Fox, 2004). In summary, the pharmacokinetic characteristics of MTX are: rapid 
plasma clearance, long half-life elimination without the need for significant change in the 
case of kidney or liver dysfunctions and persistent tissue concentrations (Stewart et al., 
1986). MTX has a very large volume of distribution, suggesting that most of the drug is 
accumulated in the tissues (Stewart et al., 1986). MTX is mostly bound to human plasma 
proteins (approximated 78%) (Batra et al., 1986). The elimination of the drug is slow, with 
a half-life of about 12 days (range 5-18 days) with persistent tissue concentrations in mice 
with tumour xenographs (Patel et al., 2013). 
One study examined the concentrations of MTX in autopsy tissue samples from 11 
patients who had received the drug 10 to 272 days before death (Stewart et al., 1986). The 
total cumulative lifetime dose of MTX for these patients ranged from 6 to 100 mg/m2. MTX 
was detected in tissues from all patients, even 272 days after administration. The highest 
concentrations were found in the thyroid, liver, and heart. The lowest concentration was 
reported in the brain (Stewart et al., 1986). Also in humans, MTX was detected 35 days 
after a single dose of 12 mg/m2 in the liver (1140 ng/g) and heart (716 ng/g) (Batra et al., 
1986). These studies were conducted in cancer patients, and the results may therefore be 
different in patients with multiple sclerosis who are dosed differently than cancer patients 
(Fox, 2004).  
The major route for the elimination of MTX from the body is biliary excretion, as renal 
clearance can account for only up to 10% of the total clearance of the drug (Fox, 2004). 
14C-labeled MTX was administered to eight patients who had advanced soft tissue cancers 
(Alberts et al., 1985) and only 6.5% of the total MTX dose administered was excreted in the 
urine as unchanged drug over the next 5 days. The mean recovery of 14C-labeled material 
in faeces over 5 days was 18.3% of the administered dose. Thirty-five days after MTX 
administration, one of the patients died of progressive kidney cancer, and approximately 
15% of the 14C dose was found in seven major organs (Alberts et al., 1985).  
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Two of the MTX metabolites were isolated from the urine of patients and 
characterized as of mono- and dicarboxylic acids resulting from oxidation of the terminal 
methyl groups in the side chains (Figure 9) (Chiccarelli et al., 1986). Regarding the inter-
species variability, the major metabolic difference between rat and humans relates to mono- 
and dicarboxylic acids that are the main products of human metabolism of MTX, whereas 
in rat, they are residual (Blanz et al., 1991b, Richard et al., 1991). Therefore, the metabolic 
differences between the species can determine that electrophilic metabolites can be formed 
in higher amounts in rats.  
Controversial data still exists whether the MTX undergoes one electron reduction or 
reduction by two electrons (Wolf et al., 1986, Duthie and Grant, 1989, Fisher and Patterson, 
1992). In fact, the reduction of MTX by flavin reductase is not facilitated, due to its low 
reduction potential (Fisher and Patterson, 1992). Thus, the preferred metabolism route of 
MTX seems to occur through two electron reduction as evidenced in studies where inhibition 
of CYP450-mediated metabolism is done (Duthie and Grant, 1989, Mewes et al., 1993, Li 
et al., 1995). It has been shown that a cyclic metabolite of MTX, the naphthoquinoxaline 
(NAPHT) (Figure 9) is a product of biotransformation of MTX in vivo in humans, pig, and rat 
(Blanz et al., 1991b, Bruck and Bruck, 2011). This metabolite has been described as the 
product of metabolism through systems containing CYP450 enzymes and peroxidases and 
it is found in urine (Blanz et al., 1991b, Bruck and Bruck, 2011). Other studies suggest that 
this metabolite has a significant role in the pharmacological anticancer activity of MTX 
(Mewes et al., 1993, Shipp et al., 1993, Feofanov et al., 1997, Panousis et al., 1997). 
After incubation of urine from MTX-treated patients with β-glucuronidase or 
sulfatase, no differences between control and test samples were found (Smyth et al., 1986). 
Therefore, glucuronidation and conjugation with sulfate did not seem to be part of the 
biotransformation of MTX in humans in that study (Smyth et al., 1986). However, other 
works confirm that the glucuronides are also urinary metabolites of MTX in humans (Batra 
et al., 1986, Blanz et al., 1991a). The human urinary glucuronide metabolite was detected 
in 1991 (Blanz et al., 1991a), whereas the MTX glutathione metabolites were only detected 
in animals (Rossato et al., 2013a) or in in vitro models (Mewes et al., 1993). In rat liver 
hepatic microsomes or S9 fraction, MTX formed glucuronic and glutathione conjugates 
(Wolf et al., 1986, Rossato et al., 2013a). Incubation of MTX with peroxidase/H2O2, in the 
presence of glutathione, led to the formation of two MTX glutathione conjugates (Blanz et 
al., 1991b).  
An in vivo study was performed to investigate whether the metabolites of MTX 
previously found in vitro were also present in liver and heart of rats, after one intraperitoneal 
administration of 7.5 mg/kg MTX 24h before (Rossato et al., 2013a). MTX and NAPHT 
metabolite were present in the heart and liver of male rats (Rossato et al., 2013a). Moreover, 
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in that study, an in vitro study was also performed using rat liver S9 fractions. In that system, 
MTX metabolism led to the formation of five metabolites all of them maintaining the 
chromophore group. Of those five metabolites, NAPHT and a new metabolite, an acetoxy 
ester derivative, were identified as resulting of MTX metabolism (Rossato et al., 2013a).  
 
 
 
Compounds R1 R2 R3 R4 
Monocarboxylic acid of MTX COOH- CH2OH- H- H- 
Dicarboxylic acid of MTX COOH- COOH- H- H- 
Glucuronide metabolites of MTX CH2OH- CH2OH- H- Glucuronide- 
 
Figure 9. The major human metabolites of MTX. 
 
 The cardiotoxicity of mitoxantrone 
Despite its initial objective, MTX is potentially cardiotoxic (Avasarala et al., 2003, 
Seiter, 2005). In 1993, Estorch et al. suggested that MTX was less cardiotoxic than 
anthracyclines (Estorch et al., 1993), but this conclusion has not been corroborated by other 
studies (Thomas et al., 2002, Avasarala et al., 2003). In fact, the cardiotoxicity of MTX 
remains a major concern for patients receiving intensive and/or prolonged therapy with MTX 
(Ehninger et al., 1990). Presently, the recommended maximum lifetime cumulative dose of 
MTX is 140 mg/m2, with 2.6 to 13% of patients developing cardiac toxicity (Seiter, 2005). 
As early as 1984, the cardiotoxicity of MTX was detected in 34 patients with advanced 
breast cancer that had never received previous chemotherapy. They were treated with MTX 
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(14 mg/m2 intravenous every 21 days) (Coleman et al., 1984). Before starting the MTX 
therapy, and every 3 months thereafter, radionuclide assessment of ventricular 
performance was obtained at rest and in response to stress. Ten patients showed a 
deterioration in ejection fraction and two of them developed congestive cardiac failure 
(Coleman et al., 1984). In another study, biopsies were examined in a small number of 
patients treated with MTX by Unverferth and colleagues. This study found cardiac 
histopathological changes similar to those found in treatment with anthracyclines. The 
nuclear chromatin changes included shrinkage, nucleolar agglutination and degeneration. 
They also observed mitochondrial swelling and tubular swelling in cardiomyocytes 
(Unverferth et al., 1983). In a study by Benjamin et al., biopsies from patients treated with 
MTX revealed dilatation of sarcoplasmic reticulum with vacuoles and myofibrillar changes 
(Benjamin et al., 1985). Those histological changes were also found to be initial cardiac 
findings in DOX therapy (Benjamin et al., 1985). In addition, an increase in cell damage with 
a higher dose of MTX was observed. Thus, the cardiac histological data of MTX indicates 
that it produces adverse changes in the human heart, which are similar to those produced 
by DOX (Benjamin et al., 1985). 
The clinical cardiotoxicity signs of MTX include decreased LVEF, congestive heart 
failure, ischemic chest pain, arrhythmias and conduction abnormalities on the ECG 
(Henderson et al., 1989, Estorch et al., 1993). Some predisposing factors for MTX 
cardiotoxicity include prior exposure to anthracyclines, thoracic radiation or pre-existing 
heart disease, although cardiotoxicity can occur in the absence of these risk factors 
(Benjamin et al., 1985) (Table 3).  
 
 Cardiotoxicity of mitoxantrone in experimental models 
The chronic cardiotoxicity has been studied in animal models in an attempt to 
discover and counteract the cardiotoxic mechanisms associated (Zbinden and Beilstein, 
1982, Perkins et al., 1984, Rossato et al., 2013a, Rossato et al., 2014). In a study by 
Zbinden and Beilstein with a twice a week administration of MTX, and then interrupted for 
18 days and then resumed with four other injections, several evaluations were made 
(Zbinden and Beilstein, 1982). After about six weeks, the authors observed significant 
changes in the ECG, elevated serum marker enzymes of cardiac damage and marked 
changes in mitochondrial structure in heart tissue (Zbinden and Beilstein, 1982). In the 
same study the authors compared the mitochondrial alterations induced by DOX and MTX 
in vivo (Zbinden and Beilstein, 1982). In these experiments, MTX injections (1 mg/kg) and 
DOX (2 mg/kg) were administered twice per week for four weeks. Each week, a group of 
animals were sacrificed and mitochondria were isolated from the heart, being the oxygen 
uptake and oxidative phosphorylation activity measured. Under these conditions, the 
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mitochondrial function was inhibited in a time dependent manner, in both MTX and DOX. 
MTX caused a marked inhibition of the activity of the pump Na+/K+ ATPase (from 41% to 
68% of the control) in the first week and that measurement remained unchanged thereafter 
(Zbinden and Beilstein, 1982). These results were in agreement with the findings of Neri 
and Cini-Neri (Neri and Cini-Neri, 1986); the later observed a progressive reduction in 
oxygen consumption and loss of ATP and phosphocreatine from rat heart samples 
incubated with DOX or MTX in vitro (Neri and Cini-Neri, 1986).  
Chronic MTX cardiotoxicity was also studied in mice with a twice per week of MTX 
administration (2 mg/kg) at weeks 1, 2, 5, 6 and 7 (Perkins et al., 1984). The rats were 
sacrificed during week 11 and the hearts were evaluated by histology. Of the 14 mice 
treated with MTX, 12 exhibited myocardial injury. The Bertazzoli scale was used to quantify 
the degree of cardiac damage and the rate 0 degree indicating that there is no difference 
between the control animals, while grade 4 indicates the most marked damage of 
myocardial fibres (Bertazzoli et al., 1979). In the Perkins et al. study, twelve animals showed 
myocardial changes: five with grade 1, four with grade 2 and three with grade 3. Infiltration 
focal mononuclear cells also occurred in three hearts (Perkins et al., 1984).  
In a more recent study, male Wistar rats were treated with 3 cycles of 2.5 mg/kg of 
MTX at day 0, 10, and 20 and then one treated group was euthanized on day 22 to evaluate 
the early MTX cardiac toxic effects, while the other group was euthanized on day 48, to 
allow the evaluation of MTX late cardiac effects (Rossato et al., 2014). Decreased levels of 
plasma total creatine kinase and creatine kinase-MB were detected in the early sacrificed 
animals while increased plasma levels of lactate were seen in the animals sacrificed later 
on. Increased cardiac relative mass and microscopic changes were evident in both treated 
groups, while activity of mitochondrial complexes was changed in both groups when 
compared to control. MTX induced an increase in the complex IV and complex V activities 
in early sacrificed treated group, while a decrease in the complex V activity was 
accompanied by the reduction in ATP content in the late-sacrificed rats (Rossato et al., 
2014). 
 
 The role of metabolism in the mitoxantrone’s toxicity 
Most studies on MTX cardiotoxicity in vitro were performed in order to evaluate the 
MTX cardiotoxicity compared to DOX, instead of trying to explain the biochemical basis of 
cardiotoxicity that is observed in MTX. However, these studies have contributed immensely 
to the overall understanding of the biochemical activity and the toxicity of the drug. 
Metabolism is involved in MTX anticancer proprieties, however, little is known about the 
influence of metabolism on MTX cardiotoxicity.  
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The oxidoreductive metabolism of MTX has a significant role on its antitumour 
effects. MTX has particular effectiveness in tumours with high contents of peroxidases 
(Blanz et al., 1991b, Bruck and Bruck, 2011), and it was verified that the inhibitory effect of 
MTX on cell growth was prevented by inhibiting the activity of CYP450 mixed oxidase 
function in a human hepatoma-derived cell line (Duthie and Grant, 1989). Similar results 
were obtained with rat hepatocytes (Mewes et al., 1993) and with human breast cancer 
cells (Li et al., 1995) incubated with MTX. Moreover, phorbol ester-stimulated human 
neutrophils can bioactive MTX through myeloperoxidase metabolism and the generated 
metabolites can form adducts with DNA, although the chemical nature the metabolites is 
unknown (Panousis et al., 1997).  
As stated, the role of MTX metabolism in its induced cardiotoxicity is poorly studied; 
however, two studies have been made that can give some hints on that subject (Shipp et 
al., 1993, Rossato et al., 2013a). In the work by Rossato et al., H9c2 cells were incubated 
with non-metabolized MTX or MTX after metabolization (Rossato et al., 2013a). It 
demonstrated that the cytotoxicity caused by MTX after metabolization was significantly 
higher than that observed in the H9c2 cells incubated with non-metabolized MTX. The co-
incubation of MTX with CYP450 and CYP2E1 inhibitors partially prevented the cytotoxicity 
caused by the drug, thus highlighting that the metabolism of MTX is relevant for its 
undesirable effects (Rossato et al., 2013a). 
The work by Shipp et al. demonstrates that the metabolite NAPHT has a higher 
potential on ATP depletion than MTX and, importantly, that the bioenergetics impairment 
hugely depends on iron availability (Shipp et al., 1993). Furthermore, the catechol ring of 
MTX and of the metabolite NAPHT seems to be relevant to the observed ATP decrease 
since ametantrone has no significant effect on ATP levels (Shipp et al., 1993). One can 
speculate by putting together all the scarce data available that MTX is not able in vivo to 
cause an initial redox cycle that is sufficient to cause an early and abrupt oxidative stress 
(as do the aglycones and semiquinones of DOX); however, MTX and its NAPHT metabolite 
rapidly accumulate in the heart (Ehninger et al., 1985, Rossato et al., 2013a) easily 
impairing ATP homeostasis in the heart, factors that seem to depend on iron (Shipp et al., 
1993).  
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The toxicity of anticancer drugs and particularly of MTX towards the cardiovascular 
system is well known. However, the mechanisms involved are largely unknown. 
Pharmacokinetic metabolism is involved in the cardiotoxicity of several anticancer drugs, 
whereas the data regarding to MTX metabolism and its relation to MTX-induced 
cardiotoxicity are scarce. The full understanding of the cardiotoxic effects induced by MTX 
and/or metabolites is important to reveal the underlying cardiac mechanisms, but also to 
pursue cardioprotective strategies when MTX is to be used.  
The main aim of this dissertation was to clarify the underlying mechanisms by which 
MTX and, its metabolite NAPHT, elicit cardiotoxicity. 
The following specific objectives were pursued: 
 Synthesis of MTX-metabolite, NAPHT, 
 Structure characterization of the obtained derivatives of MTX, 
 Evaluation of the cytotoxicity caused by MTX in different time-points and 
concentrations, 
 Evaluation of several pharmacological-active drugs towards MTX-elicited 
cytotoxicity in H9c2 differentiated cells, 
 Evaluation of cytotoxicity caused by NAPHT in different time-points and 
concentrations, 
 Evaluation of pharmacological-active drugs towards NAPHT-elicited cytotoxicity in 
H9c2 differentiated cells. 
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MATERIALS AND METHODS 
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3.1. Materials and chemicals 
MTX dihydrochloride (MTX, ≥97% purity) and peroxidase, from horseradish (Type 
II) were purchased from Sigma-Aldrich (St. Louis, MO, USA), hydrogen peroxide (H2O2) 
30% (Perhydrol®) and acetic acid glacial 100% were grade for analysis and were purchased 
from Merck (Germany), sodium acetate trihydrate for analysis was purchased from Panreac 
Quimica Sau (Barcelona, Spain). The solvents used were products pro analysis or high 
performance liquid chromatography (HPLC) grade of the firms Sigma-Aldrich, Chem-Lab 
NV, Merck, VWR Chemical and Panreac Quimica Sau. Purifications of compounds were 
performed by chromatography flash cartridge using silica gel reverse phase (RP)-18 (Grace 
Resolv®) and preparative thin layer chromatography (TLC) using Merck silica gel HPLC60 
RP-18 (GF254) plates purchased from Merck (Germany). 
The rat cardiomyocyte derived H9c2 cell line was obtained from European Collection 
of Cell Cultures [passage 8; H9c2 (2-1) cell line from rat (BDIX heart myoblast), from Sigma-
Aldrich (St. Louis, MO, USA)]. The protein assay kit Bio-Rad RC DC was purchased to Bio-
Rad Laboratories (California, USA). Sterile pipettes, 6-multiwell plates, 12-multiwell plates, 
48-multiwell plates, 96-multiwell plates and 75 cm2 flasks were obtained from Corning 
Costar (Corning, NY, USA). Phosphate-buffered saline (PBS) and penicillin/streptomycin 
10.000 μg/mL were obtained from Biochrom (Berlin, Germany). Foetal bovine serum (FBS) 
was purchased to Gibco (Invitrogen, Paisley, UK). Hanks’ balanced salt solution and 
Dulbecco’s phosphate buffered saline with calcium and magnesium were purchased to 
Gibco (Invitrogen, Paisley, UK). Other reagents, namely, trypan blue solution (0.4%), 
pyruvate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, Triton X-
100, Dulbecco’s modified eagle medium (DMEM) – high glucose, sodium bicarbonate, 
dimethyl sulfoxide (DMSO), retinoic acid (RA), neutral red (NR) solution, ethanol, trypsin 
solution, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), hydrochloric 
acid, sodium dodecyl sulfate (SDS), buthionine sulphoximine, β-NADH, N-acetyl cysteine, 
Ac-Leu-Glu-Thr-Asp-al (Ac-LETD-CHO), caspase 8 and 9 inhibitor, L-carnitine, NaOH, 3-
methyladenine, Hoechst 33258, paraformaldehyde, ethidium bromide, acridine orange, 
cycloheximide, 3,3’-dihexyloxacarbocyanine iodide (DiO6), carbonyl cyanide 3-
chlorophenylhydrazone, 1-aminobenzotriazole, 2-methyl-1,2-di-3-pyridyl-1-propanone 
(metyrapone), bovine serum albumin, luciferase from Photinus pyralis (firefly), D-luciferin 
sodium salt, glycine sodium salt, tris base, potassium hydrogen carbonate and ATP were 
obtained from Sigma-Aldrich (St. Louis, MO, USA). Ethylenediamine tetraacetic acid 
(EDTA), perchloric acid, and MgSO4 were purchased from Merck (Germany). 
3. Materials and methods 
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3.2. Methods used in the synthesis of mitoxantrone metabolites  
Melting points (mp) were obtained in a Köfler microscope and are uncorrected. 
Infrared (IR) spectra were measured in KBr microplate in a Fourier transform infrared 
spectroscopy spectrometer Nicolet iS10 from Thermo Scientific with Smart OMNI-
Transmisson accessory (Software OMNIC 8.3) (cm-1). 1H nuclear magnetic resonance 
(NMR) spectra were taken in DMSO-d6 at room temperature, on Bruker Avance 300 
instrument (300.13 MHz for 1H). Chemical shifts are expressed in  (ppm) values relative to 
tetramethylsilane as an internal reference. Coupling constants are reported in hertz (Hz). 
High resolution mass spectrometry (HRMS) mass spectra were measured on a APEX III 
mass spectrometer, recorded as Electrospray ionization mode in Centro de Apoio Científico 
e Tecnolóxico á Investigation (CACTI, University of Vigo, Spain). 
 
3.3. Synthesis and purification of mitoxantrone metabolite 
naphthoquinoxaline 
 
To a solution of MTX dihydrochloride (100 mg, 0.19 mmol) dissolved in 16 mL of 
sodium acetate buffer (pH 6), peroxidase horseradish and Perhydrol ® (1:1) were added 
and the solution was magnetically stirred 30 min at room temperature. The reaction was 
monitored by TLC [methanol (MeOH)/NH3 0.25%]. The reaction was stopped by the addition 
of a diluted hydrochloride solution. After filtration (0.2 µm, Millipore), the solvent was 
evaporated under a stream of nitrogen. 
The crude product was purified by preparative column chromatography with silica 
C18 (3 g), using a gradient of MeOH: aqueous solution of NH3 1% (5:5) until 100% of MeOH 
basified with NH3. The fractions eluted with MeOH: aqueous solution of NH3 1% (5:5) were 
gathered and the solvent evaporated furnished a blue solid corresponding to compound 
naphthoquinoxaline dicarboxylic acid (NAPHTdi); the fractions eluted with MeOH: aqueous 
solution of NH3 1% (7:3) were gathered and the solvent evaporated furnished a purple solid 
corresponding to compound NAPHT. The derivatives were further purified by the 
procedures described below. 
Compound NAPHT was purified by solid phase extraction with a cation exchange 
cartridge Discovery® DSC-SCX, with a sulfonic acid moiety following the steps: condition 
with MeOH (5 mL), loading with a solution of NAPHTdi in MeOH: water/ formic acid 1% (5 
mL); elution with MeOH (10 mL) followed by a solution of MeOH/NH3 1% (10 mL); the basic 
fractions were collected and the solvent evaporated under reduced pressure to afford a 
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purple solid corresponding to 8,11-dihydroxy-4- (2-hydroxyethyl) -6-[[2-[(2-hydroxyethyl)-
amino]- ethyl]- amino]- 1,2,3,4,7,12- hexahydronaphtho- [2,3-f]- quinoxaline- 7,12- dione 
[NAPHT, 97% purity by HPLC-diode array detector (DAD), 20 mg, 24% isolated yield]: mp 
112-115ºC (MeOH); IR (KBr) ʋmax: see table 4. (DMSO-d6, 75.47 MHz) δ = see table 5. 
Anal. Calc. for C22H26N4O6: 442.1852, found: 442.18469. Compound NAPHTdi was purified 
by a C18 preparative column chromatography. Fractions eluted with MeOH: aqueous 
solution of NH3 1% (7:3) were collected, reunited and the solvent evaporated to furnish a 
blue solid corresponding to 3-((2-((4-(2-carboxyethyl)-8,11-dihydroxy-7, 12-dioxo-1, 2, 3, 4, 
7, 12- hexahydronaphtho- [2,3-f]-quinoxalin-6-yl)amino)ethyl) amino)propanoic acid (75% 
purity by HPLC-DAD, 1 mg, 1%): mp 65-70ºC (MeOH); IR (KBr) ʋmax: see table 4. 1H NMR 
(DMSO-d6, 300.13 MHz) δ = see table 5. Anal. Calc. for C22H22N4O8: 470.1438, found: 
470.17950. 
 
3.4. High performance liquid chromatography analysis of mitoxantrone 
derivatives 
 
HPLC analysis of the synthetic products was performed in a Spectrasystem P4000 
Autosampler 3000, Thermo Fisher ScientificTM (USA), equipped with a DAD ultraviolet (UV) 
8000, and using a C18 column (5 µm, 150 mm x 4.6 mm I.D.) from Fortis BIO Technologies 
(Cheshire, United Kingdom). The injected volume was 10 μL and the mobile phase was 
monitored at 254 nm. ChromQuestTM  5.0 software, Version 3.2.1, Thermo Fisher 
ScientificTM (USA) managed chromatographic data. HPLC ultrapure water was generated 
by a Milli-Q system (Millipore, Bedford, MA, USA). The mobile phase was degassed for 15 
min in an ultrasonic bath before use. A linear gradient from 10 to 80% of eluent B within 30 
min [eluent A: 0.1% aqueous solution of CF3COOH; eluent B: 100% MeOH] was used at a 
constant flow rate of 0.5 mL/min. All samples were dissolved in MeOH and filtered through 
a hydrophilic Durapore-GV membrane of 0.45 mm pore size (Millipore) before injection. The 
retention factor (k) was determined as [k= (tR–t0)/t0] and t0 was considered to be equal to 
the peak of the solvent front. 
 
3.5. Cell culture model used in the toxicological evaluation 
The toxicological evaluation of MTX and of NAPHT was done in vitro, using H9c2 
cells. The H9c2 cell line was isolated from the ventricular part of a thirteenth-day rat heart 
embryo and presents a myoblastic proliferative phenotype while maintained in normal 10% 
FBS-containing culture media (Kimes and Brandt, 1976). H9c2 is considered a valuable 
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model to assess in vitro cardiotoxicity (Kimes and Brandt, 1976), especially due to its 
metabolic features, which are comparable to those found in rat heart (Zordoky and El-Kadi, 
2007). 
 
 Subculturing H9c2 
H9c2 cells were maintained in the proliferative state in the presence of 10% FBS. 
H9c2 cell were grown in complete medium: DMEM with high glucose supplemented with 
10% FBS and antibiotics (10 000 units/mL penicillin and 10 000 µg/mL streptomycin) at 
37°C with 5% CO2. Cell passaging was done by trypsinization. All experiments were carried 
out with cells before reaching 70–80 % confluence (Ruiz et al., 2012). The cell line was 
used between passage 15 and 30. 
 
 H9c2 cells differentiation 
Differentiation into a “cardiac like” phenotype was induced with 1% FBS in culture 
medium supplemented with RA 10 nM (medium changed every two-days) (Pereira et al., 
2011, Ruiz et al., 2012).  The differentiation and decreased proliferation was assessed by 
contrast phase microscopy and the fluorescent nuclear dye Hoechst 33258 (Soares et al., 
2013).  
 
3.6. Cytotoxicity assays 
After trypsinization, cells were placed in 48 well-plates, 12 well-plates, or 6 well-
plates with the density of 24 000 cells/mL. After the 7-day differentiation protocol described, 
H9c2 cells were incubated with different chemicals. The first tests performed were the 
cytotoxicity curves of MTX and metabolite, combined with the morphological evaluation, 
using by phase contrast microscopy. After cell differentiation protocol, cells were incubated 
with MTX in concentrations that ranged from 0.01 to 5 µM and NAPHT in concentrations 
that ranged from 1 to 5 µM, and two time-points were selected (24 and 48h) for the 
cytotoxicity tests. The cytotoxicity tests used were: LDH leakage assay, the MTT assay and 
the NR uptake assay (Soares et al., 2013).  
 
 Morphological evaluation 
3.6.1.1. Contrast phase microscopy 
Cell cultures were assessed morphologically by phase contrast microscopy at the 
selected time-points in 6 or 12 well-plates. Cells were examined in a Nikon Eclipse TS100 
equipped with a Nikon DS-Fi1 camera (Japan). 
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3.6.1.2. Hoescht nuclear staining 
For Hoechst staining, H9c2 cells were seeded in 48 well-plates with 24 000 cells/mL 
and differentiated or not for 7 days. After reaching the end-point, cells were fixed in 4% 
paraformaldehyde (10 min, 4ºC) and washed with PBS (three times). Cells were then 
stained with the nuclear dye Hoechst 33258 for 10 min at 37°C (protected from light), after 
which they were washed with PBS (three times) at room temperature. Cells were examined 
in Nikon Eclipse TS100 equipped with a Nikon DS-Fi1 camera using a fluorescent filter 
(λexcitation maximum = 346 nm and λemission maximum = 460 nm) (Soares et al., 2013). 
 
3.6.1.3. Ethidium bromide and acridine orange staining 
The fluorescent DNA-intercalating dyes ethidium bromide and acridine orange are 
suitable to distinguish live from dead cells. Also, the ethidium bromide and acridine orange 
staining allows the microscopic morphological discrimination between necrotic and 
apoptotic cell death and acridine largely accumulates in acidic vesicles. Ethidium 
homodimers do not penetrate intact cellular membranes. Therefore, ethidium bromide only 
intercalates with nucleic acids if the outer cellular membrane has disintegrated. In contrast, 
the fluorescent cationic dye acridine orange diffuses through intact membranes of live cells. 
When bound to DNA, it reaches an emission maximum at 525 nm (Capela et al., 2013). The 
staining of H9c2 was done after removing all the growth medium of the 48-wells after the 
incubation period with MTX or NAPHT. To the cells were added 200 µL of heated PBS with 
Ca2+e Mg2+, and then 8 µL of the stock solution ethidium bromide and acridine orange 
solution (0.5 mg/mL). A 5 min incubation in the dark was followed. After removing the 
ethidium bromide and acridine orange, cells were washed with warm PBS with Ca2+e Mg2+ 
(200 µL/ well) and then new medium was added. Cells were examined in Nikon Eclipse 
TS100 equipped with a Nikon DS-Fi1 camera, using a standard fluorescein filter (λexcitation = 
485 nm and λemission = 525 nm). 
 
3.7. Cytotoxicity tests 
 Lactate dehydrogenase kinetic leakage assay 
H9c2 cells were seeded in 48-well plates. For MTX and NAPHT evaluation of 
induced cell death, cells were incubated for 24 or 48h with different drug concentrations. 
After cell treatment, cell death was evaluated as the measurement of membrane integrity 
seen by the percentage of LDH release over the total LDH. For experiments with caspase 
8 and 9 inhibitor, Ac-LETD-CHO (200 µM and 100 µM) (Shi and Shen, 2008), the antioxidant 
N-acetyl cysteine, a glutathione precursor and reactive species scavenger (1 mM) (Martins 
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et al., 2013, Rossato et al., 2013b), the buthionine sulphoximine, an inhibitor of gamma-
glutamylcysteine synthetase (50 µM) (Ferreira et al., 2013), L-carnitine, a mitochondrial 
enhancer (2mg/mL) (Rossato et al., 2013b), 3-methyladenine, an autophagy inhibitor (2.5 
mM) (Soares et al., 2014), 1-aminobenzotriazole, a suicide substrate for CYP450 (0.5 mM) 
(Shi et al., 2011a), the addition of these compounds was done 1h prior to the addition of 
MTX 2 µM. In the case of NAPHT 2 µM incubation with N-acetyl cysteine (1 mM), this later 
molecule was added 1h prior to the addition of NAPHT. 
The quantification of LDH activity was made using a colorimetric method, based on 
the reversible reduction of pyruvate to lactate (last step of anaerobic glycolysis) in the 
presence of β-NADH, as described below (Capela et al., 2006). 
 
3.7.1.1. Extracellular lactate dehydrogenase activity 
LDH can be found outside the cell only when there is cell death (apoptotic or necrotic 
type) or lysis of cytoplasmatic membrane. The extracellular activity of LDH was determined 
after the suitable amount of medium was added to β-NADH 0.15 mg/mL solution at room 
temperature, in 96-microplate wells. Finally, pyruvate 22.7 mM was added to start the 
reaction. NADH oxidation to NAD+ was measured at 340 nm for 4 and a half min, using a 
96-well plate reader (BioTek Instruments, Powerwave X, USA). The slope of the curve 
obtained was used for the calculation of the % LDH leakage (Capela et al., 2006).  
 
3.7.1.2. Total lactate dehydrogenase activity 
Total LDH activity was determined after adding 20 µL of Triton X-100 5% to each 
well and incubated at 37°C for 30 min. The cells were totally lysed by this procedure and 
then the activity of the LDH obtained was evaluated as described previously. Medium was 
added to 0.15mg/mL β-NADH solution at room temperature, in a 96-well microplate. Finally, 
pyruvate 22.7mM was added to start the reaction as described in the previous section 
(Capela et al., 2006). Cell death was quantified as a measurement of membrane integrity 
and evaluated by the percentage of LDH released over total LDH. 
 
 MTT reduction assay 
The MTT assay was first done to evaluate the cytotoxicity of MTX and NAPHT in 
differentiated H9c2 cells. This colorimetric assay relies mostly on the ability of mitochondrial 
complexes (or other dehydrogenases) to convert the soluble yellow tetrazolium dye, MTT, 
into an insoluble blue formazan product that can be measured at 550 nm (Costa et al., 2009, 
Soares et al., 2013). After the removal of culture medium, to each well was added 200 µL 
of fresh medium (DMEM 1% FBS and 10 nM RA) and 20 µL of the MTT solution (final 
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concentration of MTT 500 µg/mL). Subsequently, cells were incubated at 37ºC for 4h. The 
reaction was stopped by adding 200 µL of 10% SDS in 0.01 M hydrochloric acid solution 
followed by an overnight incubation at 37ºC, to allow solubilization of the formed formazans. 
Finally, the formed formazans were measured at 550 nm using a 96-well plate reader 
(Capela et al., 2006). The percentage of MTT reduction of control/vehicle cells was set to 
100%, and the effects resulting from the incubation with MTX or metabolite were expressed 
as the percentage to the respective controls or vehicle. 
The MTT test was also done to evaluate the effects of cycloheximide, a glutarimide 
antibiotic (10 µg/mL) (Gupta et al., 2006), and metyrapone, CYP450 inhibitor (0.5 mM) 
(Rossato et al., 2013b), towards MTX cytotoxicity. Cycloheximide and metyrapone were 
added 1h before MTX. 
 
 Neutral Red lysossomal uptake assay 
For this assay, H9c2 cells were seeded in 48-well plates. The amount of NR dye 
incorporated in the cells represents lysossomal functionality, as this dye easily penetrates 
viable cell membranes and accumulates intracellularly in lysosomes (Soares et al., 2013). 
At the end of the incubation time, the cellular medium was removed and 250 µL/well of NR 
solution (33 mg/mL of NR in DMEM 1% FBS) was added. Then, plates were incubated for 
3h at 37ºC, protected from light. After this time, NR solution was removed and 200 µL/well 
of the solution formed by 50% ethanol/1% acetic acid was added to extract the NR dye 
meanwhile captured within the cells. The plates were then placed in a microplate shaker for 
15 min, at room temperature and protected from light. Absorbance was measured at 540 
nm, in a 48-well plate reader [Biotech Synergy HT (VT, USA)] and results were compared 
to control/ vehicle wells whose media of values was set to 100% (Soares et al., 2013). 
The NR test was done to access the effects of 3-methyladenine (2.5 mM), 1-
aminobenzotriazole (0.5 mM) and metyrapone (0.5 mM) following the exposure to MTX (and 
also 3-methyladenine in the case of NAPHT) in H9c2 differentiated cells. Those compounds 
were added 1h before MTX (or NAPHT). 
 
3.8. Evaluation of mitochondrial potential 
The evaluation of the mitochondrial potential was done according to Freitas et al., 
with some modifications (Freitas et al., 2013). Briefly, 7-days differentiated cells were 
incubated for 12h with MTX or NAPHT and then cells were incubated for 30 min at 37ºC 
with DiO6 at the final concentration of 50 µM per well. In each condition and experiment, a 
well was placed with DiO6 and the mitochondrial uncoupling agent, carbonyl cyanide 3-
chloro-phenylhydrazone, at the final concentration 20 µM. Also, a well in each condition was 
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tested without any DiO6 as to evaluate if any component of the medium or if MTX or NAPHT 
conditions had any residual fluorescence that interfered with the fluorescence readings. 
After the 30 min incubation time, the cells were then washed 2 times with warmed PBS with 
Ca2+e Mg2+. Photographs were taken in a fluorescent microscope (Nikon Eclipse TS100 
equipped with a Nikon DS-Fi1 camera) with the standard fluorescein filter (λexcitation = 485 
nm and λemission = 520 nm). 
 
3.9. Determination of cellular ATP levels 
For this assay, H9c2 cells were seeded in 6-well plates. The ATP was evaluated in 
differentiated H9c2 cells incubated for 24h with 2 and 5 μM of MTX, and 2 and 5 μM NAPHT. 
After the incubation period, medium was discarded and cells were washed with cold PBS 
with Ca2+e Mg2+ (750 μL/well). The PBS used for washing was discarded. Another 750 
μL/well cold PBS with Ca2+e Mg2+ was added and cells were scrapped. Two wells per each 
condition were collected and centrifuged at 5 000 rpm, 4°C, for 10 min. The supernatant 
was rejected and to the pellet was added 200 μL of cold 5% perchloric acid. Then, the 
obtained samples were vortexed and centrifuged at 13 000 rpm, for 10 min, at 4°C. The 
acidic supernatant was collected for ATP determination and placed at -80°C. The pellet was 
used for protein determination and stored at -20°C. 
The ATP levels were determined by bioluminescence through the reaction with the 
firefly luciferin-luciferase system (Costa et al., 2007). D-Luciferin 90.9 mg/L stock reagent 
and luciferase from Photinus pyralis (firefly) (3 000 000 U/mL final concentration) were 
prepared in luciferin-luciferase buffer (50 mM glycine, 10 mM MgSO4, 1 mM Tris, 0.55 mM 
EDTA, 0.1% bovine serum albumin, pH = 7.6) and light protected aliquots were stored at -
20ºC until use. Before the assay, luciferin-luciferase reaction system was constituted by 
adding the two solutions and then kept at room temperature. Briefly, the assay consisted of 
neutralizing 150 μL of the acidic samples, standards or blank with 150 μL of 0.76 M of 
KHCO3, followed by vortex, and centrifugation for 10 min at 13 000 rpm (4ºC). One hundred 
μL of neutralized supernatants was added to a 96-well white microtiter plate, followed by 
addition of 100 μL/well of the luciferin-luciferase reagent. The reading was immediately 
done in the plate reader [Biotech Synergy HT (VT, USA)]. Light output was given as the 
integral relative light units. The assay was made sequentially with few measurements in 
each reading in order to avoid loss of the bioluminescence signal (Costa et al., 2007). The 
levels of ATP were expressed as ATP levels per amount of protein.  
 
3.10. Protein determination  
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The protein content assay was determined using the protein assay kit Bio-Rad RC 
DC, according to the manufacturer’s instructions. Bovine serum albumin was used as 
protein standard and the calibration curve varied from 200 μg/mL to 1 200 μg/mL in 0.3 M 
NaOH. Five μL of samples, standards or blank was added in duplicated to a 96-well 
microtiter plate, followed by addition of 25 μL of Reagent A and 200 μL of Reagent B, light 
protected. The microtiter plate was kept protected from the light for 15 min, after which the 
absorbance was measured at 750 nm [BioTek Instruments, Powerwave X, (VT, USA)]. 
 
3.11. Statistical analysis 
The data is presented as means ± standard deviation (SD) of different independent 
experiments. Statistical analysis was carried out by the non-parametric Anova (Kruskal-
Wallis test) followed by a Dunn’s post hoc test once a significant p was achieved. When the 
distribution was normal, one-way Anova was performed followed by Tukey’s post hoc test. 
Statistical significance was considered with a p values < 0.05. All statistical analysis were 
assessed using the GraphPad Prism 6 software program (San Diego, CA, USA). 
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4. 
RESULTS  
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4.1. Synthesis of the mitoxantrone metabolite naphthoquinoxaline 
 
The synthesis of the MTX metabolites was accomplished through the horseradish 
peroxidase (HRP)-catalysed H2O2 oxidation of MTX and the products isolated from this 
reaction are depicted in Figure 10. 
 
 
 
Figure 10. The isolated products of the incubation of MTX with HRP: NAPHT and NAPHTdi. 
 
Although with the enzymatic oxidation of MTX, several derivatives could be 
observed by chromatographic analysis, only two purified derivatives were isolated and 
identified as NAPHT, corresponding to 8, 11-dihydroxy-4-(2-hydroxyethyl)-6-[[2-[(2-
hydroxyethyl)-amino]ethyl]-amino]-1,2,3,4,7,12-hexahydronaphtho-[2,3-f]-quinoxaline-7,12 
-dione, and NAPHTdi, corresponding to 3-((2-((4-(2-carboxyethyl)-8,11-dihydroxy-7,12-
dioxo-1,2,3,4,7,12-hexahydronaphtho-[2,3-f]-quinoxalin-6-yl)amino)ethyl)amino) propanoic 
acid, already proposed as a product of the peroxidase-catalyzed H2O2 oxidation of MTX by 
Bruck and colleagues (Bruck and Bruck, 2011). First attempts to purify the crude product 
using normal-phase chromatography were unsuccessful due to the retention of MTX 
derivatives in the stationary phase. Thus, procedures involving reverse-phase (for both) 
and/or ion exchange chromatography (for NAPHT) that have shown great versatility and 
capability for retaining and separating a variety of charged polar compounds, were used in 
the isolation of derivatives NAPHT and NAPHTdi (see Methods section).  
4. Results  
84 
The purity for the precursor MTX and of the isolated products NAPHT and NAPHTdi 
were determined by diode-array analysis performed in a HPLC-DAD (Figure 11) and were 
of 98%, 97%, and 75%, respectively. 
 
 
 
Figure 11. Representative HPLC chromatograms (left) [= 254 nm, C18, linear gradient from 
10 to 80% of eluent B within 30 min (eluent A: 0.1% aqueous solution of CF3COOH; eluent B: 100% 
MeOH)] and UV spectra (right) of MTX and isolated products NAPHT and NAPHTdi. 
 
MTX and the derivatives NAPHT and NAPHTdi showed similar spectral features 
between 200 and 300 nm, but slight differences were observed in the visible range (Figure 
11, left column). MTX shows absorbance maxima at 610 and 660 nm as previously reported 
(Bruck and Harvey, 2003); NAPHT revealed absorbance maxima at 584, 633 nm and a 
shoulder at 550 nm, which was previously described for this two-electron oxidized 
metabolite (Kolodziejczyk et al., 1988, Reszka and Chignell, 1996). For NAPHTdi a similar 
profile to NAPHT spectrum was observed but with reduced intensity. 
The crude product from the peroxidase oxidation of MTX was also analysed by 
HPLC-DAD to determine the yields of the isolated derivatives NAPHT and NAPHTdi. A 
representative chromatogram is shown in Figure 12. 
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Figure 12. Representative HPLC chromatogram [= 244 nm, C18, linear gradient from 10 to 
80% of eluent B within 30 min (eluent A: 0.1% aqueous solution of CF3COOH; eluent B: 100% 
MeOH)] of 6.63 mg/mL solution of the crude product. MTX (k = 5.1), NAPHT (k = 6.3), NAPHTdi (k 
= 7.5).  
 
Analysis of the reaction mixture by HPLC (Figure 12) indicated that the majority of 
MTX reacted after 30 min. The calculated HPLC yields for the products NAPHT and 
NAPHTdi (considering their areas as MTX) were 85% and 1.2%, respectively. The 
precursor MTX at that time point represented 2% of the total molecules. 
 
4.2. Structure determination of naphthoquinoxaline and 
naphthoquinoxaline dicarboxylic acid 
 
The structure elucidation of NAPHT and NAPHTdi was established by HRMS, IR, 
and by NMR techniques. The HRMS-ESI gave for NAPHT the accurate molecular mass of 
442.18469 and the molecular formula C22H26N4O6 and for NAPHTdi the accurate molecular 
mass of 470.17950 and the molecular formula C22H22N4O8. These data allowed to suggest 
that the isolated compounds NAPHT and NAPHTdi, corresponded to 8,11-dihydroxy-4-(2-
hydroxyethyl)-6-[[2-[(2-hydroxyethyl)-amino]-ethyl]-amino]-1,2,3,4,7,12-hexahydronaphtho 
-[2,3-f]-quinoxaline-7,12-dione and 3-((2-((4-(2-carboxyethyl)-8,11-dihydroxy-7,12-dioxo-
1,2,3,4,7,12-hexahydronaphtho-[2,3-f]-quinoxalin-6-yl)amino)ethyl)amino) propanoic acid, 
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respectively. The IR data of MTX, NAPHT, and NAPHTdi are presented in Table 4 and 
Figures 13, 14, and 15, respectively. 
 
 Table 4. IR data for compounds MTX, NAPHT, and NAPHTdi. 
 
Compound 
 
Group  (cm-1) 
 
OH 3412, 3401 
N-H 3073, 3093 
C-H 
2952, 2921, 2847, 
2779 
N-H 1632 
C=O 1605, 1563 
C=C (Ar) 1546, 1528, 1510 
C-H 1486, 1450, 1392 
C-N, C-O 1208, 1222 
 
OH 3443 
C-H 2925 
N-H 1631 
C=O 1602 
C=C (Ar) 1560, 1541 
C-H 1458, 1385 
C-N, C-O 1340, 1248 
 
OH 3424 
C-H 2922, 2852 
N-H 1644 
C=O 1633, 1602  
C=C (Ar) 1567, 1501 
C-H 1384, 1340 
C-N, C-O 1247, 1213 
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Figure 13. IR spectra of MTX. 
 
 
 
Figure 14. IR spectra of NAPHT. 
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Figure 15. IR spectra of NAPHTdi. 
 
The IR data of MTX and their derivatives NAPHT and NAPHTdi were similar and 
although indicated the presence of derivatives of MTX for NAPHT and NAPHTdi, spectra 
were not suggestive of the transformations occurred. 
The 1H NMR data of MTX, NAPHT, and NAPHTdi are presented in Table 5 and 
Figures 16, 17, and 18, respectively. 
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Table 5. 1H NMR data¥ of MTX, NAPHT, and NAPHTdi. 
 
¥ Values in ppm (δH) relative to Me4Si as an internal reference. J values are in Hz. [singlet 
(s); triplet (t), multiplet (m)]. 
 
 
H 
  
 
1-OH 
13.44,s, 2H  
8-OH 14.36,s, 1H 8-OH  14.26, s ,1H 
4-OH 11-OH 13.56,s, 1H 11-OH 13.55, s, 1H 
5-NH 
10.41, brs, 2H 
2-NH 10.95, s, 1H 2-NH 10.91, s, 1H 
8-NH 6-NH 11.34, s, 1H 6-NH 11.33, s, 1H 
H-2  
7.65, s, 2H 
H-9 
7.00 – 6.97, 2H 
H-9 7.03 – 7.01, m, 
2H H-3 H-10 H-10 
H-6 
7.19, s, 2H H-5 6.19, s, 1H H-5 6.23, s, 1H 
H-7 
4’-OH 5.34, brs, 2H 4’’-OH 4.96, s, 1H 4’’-OH 4.90-4.83, m, 1H 
4’’-OH 5.34, brs, 2H 2’-OH 4.66, s, 1H 2’-OH 4.14-4.13, m, 1H 
H-1’ 
3.89-3.87, m, 2H 
H-1’’ 3.72, m (under 
H2O) 
H-1’’ 3.38,  m (under 
H2O) H-1’’ H-1 H-1 
H-2’ 
3.69-3.66, m, 4H 
H-2’’ 3.63, m (under 
H2O) 
H-2’’ 3.18, m, (under 
H2O) H-2’’ H-4 H-4 
H-3’ H-3’’ 
2.89, t, 4H 
H-3’’ 
3.16, m, 4H 
H-3’’ H-1’ H-1’ 
H-4’ 
3.07-3.05, m, 2H 
H-2’ 
2.69, t, 4H 
H-2’ 
H-4’’ H-4’’ H-4’’ 
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Figure 16. 1H NMR spectra of MTX. 
 
 
 
Figure 17. 1H NMR spectra of NAPHT. 
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Figure 18. 1H NMR spectra of NAPHTdi. 
 
The multiplicity and coupling constants of the protons observed in the 1H NMR 
spectrum of MTX showed the existence of two symmetrical 1, 4-disubstituted benzene 
rings, the signals of the protons of the hydroxyl and amine groups and of the aliphatic chain.  
In turn, the 1H NMR spectrum of NAPHT showed a different pattern of substitution 
in the aromatic ring while the proton signals of methylene groups, characteristic of the 
aliphatic chains, were maintained. The fusion of the piperazine ring with C-5/C-6 of the 
aromatic ring of the anthraquinone is evidenced by the lack of H-6 signal and the presence 
of a singlet corresponding to H-7 and of two aromatic protons, corresponding to H-2 and H-
3. The proposed structure was in agreement with the result obtained from the HRMS. 
The amount of NAPHTdi isolated allowed obtaining the 1H spectrum, which revealed 
a similar pattern of substitution in the aromatic ring when compared to NAPHT while signals 
of deshielded protons were observed at 4.1 and 3.1 ppm for the methylene groups 
characteristic of the aliphatic chains for the proposed structure of NAPHTdi. The proposed 
structure was in agreement with the result obtained from the HRMS. 
 
4.3. Differentiation alters cell division and microscopic characteristics 
of H9c2 
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The differentiation protocol was conducted with 1% FBS and RA for 7 days. The 
differentiation by 10 nM RA and 1% FBS by 7 days led to morphological changes making 
cells more resembled to the cardiac phenotype. There were substantial differences between 
undifferentiated cells and differentiated cells, which are illustrated in Figure 19. At panel 
19B and D, two detailed Figures of both differentiated and undifferentiated H9c2 cells 
cultivated for 7 days in multi-well plates are presented. The differentiation protocol 
dramatically reduced cell division. In fact, cellular density was substantially higher in 
undifferentiated cells cultivated for 7 days with 10% FBS medium without RA. Also, while 
inhibition of cell division occurred, the cell bodies of differentiated cells became smaller and 
fusiform when compared to undifferentiated cells, which exhibit a large and flat cell body. 
Overall, differentiated cells showed to established a more organized network bearing a 
more cardiac-like morphology, as shown by phase-contrast morphology. The differentiation 
also resulted in a lower proliferation rate as verified by Hoechst 33258 staining. 
 
 
 
Figure 19. Fluorescence microscopy (Hoechst 33258 staining, A and C) and phase contrast 
microscopy images (B and D) of undifferentiated (A and B) and differentiated (C and D) H9c2 cells 
for 7 days. Images are representative of three independent experiments (scale bar 100 μm). 
 
4.4. Toxicological evaluation of mitoxantrone   
 Microscopic evaluation of mitoxantrone-incubated H9c2 cells 
Cells were morphologically assessed after 24h exposure to MTX. H9c2 cells were 
incubated with MTX (2 and 5 μM), as described in the Methods section. Phase-contrast 
microscopy and Hoescht staining were used. Phase-contrast microscopy, after 24h 
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incubation, revealed cell death, with intensifying features of cell death when increasing 
concentrations (Figure 20). In particular, H9c2 cell exposed with 5 μM of MTX showed signs 
of loss of membrane integrity and decrease in cell number (Figure 20C and 20F). No signs 
of nuclear alteration were found by Hoescht staining. At 48h, the cell injury was more 
increased in MTX-incubated cells (data not shown). 
 
 
 
Figure 20. Fluorescence microscopy (Hoechst 33258 staining) (A, B, C), phase contrast 
microscopy (D, E, F) images of differentiated H9c2 cells after incubation with 2 and 5 μM of MTX for 
24h. Control (A and D), MTX 2 μM (B and E), MTX 5 μM (C and F). Images are representative of 
three independent experiments (scale bar 100 μm). 
 
Ethidium bromide/ acridine orange staining was also used for evaluate MTX effects 
on H9c2 cells. Through this method, living cells appear with a regular-sized green 
fluorescent nucleus, as shown in control H9c2 in Figure 21A. The number of cells largely 
decreased with increased MTX concentration, but cells present in the field remained with 
green nucleus, although with cytoplasmatic injury (Figure 21C). 
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Figure 21. Ethidium bromide and acridine orange (A, B, C) images of differentiated H9c2 
cells in control and in cells incubated with 2 and 5 μM of MTX for 24h. Control (A), MTX 2 μM (B), 
MTX 5 μM (C). Images are representative of three independent experiments (scale bar 100 μm). 
 
Assessment of mitochondrial membrane potential in differentiated H9c2 cells 
incubated with 2 μM of MTX (B) and 5 μM of MTX (C) for 12h (Figure 22) was done. Lower 
levels of fluorescence resulting from MTX treatment were observed, suggesting the 
depolarization of mitochondrial membrane potential at 12h. This depolarization effect seems 
dose dependent (Figure 22C).  
 
 
 
Figure 22. Mitochondrial transmembrane potential (A, B, C) images of differentiated H9c2 
cells after incubation with 2 and 5 μM of MTX for 12h. Control (A), MTX 2 μM (B), MTX 5 μM (C). 
Images are representative of three independent experiments (scale bar 100 μm). 
 
 Mitoxantrone led to a time- and concentration-dependent 
mitochondrial dysfunction 
The ability of MTX to interfere with MTT reduction was evaluated at 2 time-points 
(24 and 48h) and with several concentrations (0.01 to 5 µM). At 24h (Figure 23A), MTX at 
concentration 0.1 µM already caused significant cytotoxicity when compared to control cells, 
being the highest dose tested (5 µM) able to decrease the levels of MTT reduction to 85.99 
± 8.52%. At 48h, as can be seen in Figure 23B, the cytotoxicity elicited was even higher, 
when compared to control and the same concentrations in the earlier time point. 
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Figure 23. Mitochondrial dysfunction evaluated by MTT reduction assay in differentiated 
H9c2 cells incubated with 0.01, 0.1, 1, 2 and 5 μM of MTX for 24 (A) and 48h (B). Results are 
presented as mean ± SD of 5 independent experiments (total of 30 wells). Statistical analysis were 
performed using Kruskal–Wallis test, followed by the Dunn’s post hoc test (*p < 0.05, ***p < 0.001, 
****p < 0.0001 vs. control; ##p < 0.01, ####p < 0.0001 vs. 0.01 µM; $p < 0.05, $$$$p < 0.0001 vs. 0.1 
µM; +p < 0.05 vs. 2 µM). 
 
 Mitoxantrone was only able to cause significant loss of 
membrane integrity at the highest concentrations tested  
The ability of MTX to cause LDH leakage to the extracellular medium was tested at 
2 time-points (24 and 48h) and with several concentrations (0.01 to 5 µM). At 24h (Figure 
24A), only the higher concentrations of MTX (1, 2 and 5 µM) caused significant cellular 
membrane integrity loss when compared to control cells. In Figure 24B, the data obtained 
after the 48h incubation of H9c2 differentiated cells is observed. MTX, at 48h, caused a 
significant decrease in cellular toxicity, being observed that at 1 µM MTX the viability was 
64.08 ± 8.26%, 2 µM MTX the viability was 43.47 ± 7.49% and at 5 µM the viability was 
27.98 ± 9.92%. 
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Figure 24. Cellular viability evaluated using the LDH leakage assay (% of extracellular 
LDH/total LDH) in differentiated H9c2 cells incubated with 0.01, 0.1, 1, 2 and 5 μM of MTX for 24 (A) 
and 48h (B). Results are presented as mean ± SD of 5 independent experiments (total of 30 wells). 
Statistical analysis was done using the Kruskal–Wallis test, followed by the Dunn’s post hoc test 
(****p < 0.0001 vs. control; ####p < 0.0001 vs. 0.01 µM; $$p < 0.01, $$$$p < 0.0001 vs. 0.1 µM; &&p < 
0.01, &&&p < 0.001 vs. 1 µM). 
 
 Mitoxantrone caused a significant lysosome uptake dysfunction 
in H9c2 differentiated cells 
After 24 and 48h incubation with several concentrations of MTX (0.01 to 5 µM), the 
lysossomal uptake of NR was evaluated. At 24h (Figure 25A), the highest concentrations 
of MTX (1, 2 and 5 µM) caused a substantial impairment of lysossomal uptake of NR when 
compared to control cells. At 48h (Figure 25B), lysossomal functionality was even more 
impaired in MTX highest concentrations (1, 2 and 5 µM). At 48h, the H9c2 cells incubated 
MTX 1 µM had 58.98 ± 15.41%, 2 µM had 37.81 ± 7.34 %, and 5 µM 24.64 ± 4.07% NR 
uptake ability when compared to control cells (Figure 25B). 
 
 
 
Figure 25. NR uptake (% of control) in differentiated H9c2 cells incubated with 0.01, 0.1, 1, 
2 and 5 μM of MTX for 24 (A) and 48h (B). Results are presented as mean ± SD of 5 independent 
experiments (total of 30 wells). Statistical analysis was done using the Kruskal–Wallis test, followed 
by the Dunn’s post hoc test (****p < 0.0001 vs. control; ##p < 0.01, ####p < 0.0001 vs. 0.01 µM; $p < 
0.05, $$p < 0.01, $$$$p < 0.0001 vs. 0.1 µM; &&&p < 0.001, &&&&p < 0.0001 vs. 1 µM). 
 
 Buthionine sulphoximine, an inhibitor of gamma-
glutamylcysteine synthetase, had no effect on cellular death caused 
by mitoxantrone incubation in H9c2 cells 
Buthionine sulphoximine, an inhibitor of gamma-glutamylcysteine synthetase, at 50 
µM concentration, was pre-incubated in H9c2 cells, to access if the decrease of glutathione 
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synthesis caused any effect on the cytotoxicity caused by MTX. Buthionine sulphoximine 
did not cause any significant alteration on the cell death caused by the 48h incubation of 2 
µM MTX (Figure 26). At 48h, 2 µM MTX had 53.95 ± 5.26% viability, whereas the condition 
2 µM MTX plus buthionine sulphoximine had a viability of 50.96 ± 8.30% (Figure 26). The 
use of buthionine sulphoximine at 50 µM did not cause any significant change in cellular 
viability when compared to control cells.  
 
 
 
Figure 26. Cellular viability evaluated using the LDH leakage assay (% of extracellular 
LDH/total LDH) in differentiated H9c2 cells incubated with 2 μM of MTX and buthionine sulphoximine 
(BSO), an inhibitor of gamma-glutamylcysteine synthetase at 50 µM and BSO + MTX, for 48h. 
Results are presented as mean ± SD of 4 independent experiments (total of 20 wells). Statistical 
analysis was done using the Kruskal–Wallis test, followed by the Dunn’s post hoc test (****p < 0.0001 
vs. control; $$$$p < 0.0001 vs. BSO 50 µM). 
 
 N-acetyl cysteine, a glutathione precursor and reactive species 
scavenger, was not able to revert the cell death caused by 
mitoxantrone incubation  
N-acetyl cysteine, a glutathione precursor and reactive species scavenger 
(Avantaggiato et al., 2014), at 1 mM concentration, was used in H9c2 cells. The antioxidant, 
N-acetyl cysteine, did not cause any significant alteration on the cell death caused by the 
48h incubation of 2 µM MTX (Figure 27). At 48h, 2 µM MTX had 52.20 ± 4.38% viability, 
whereas the condition 2 µM MTX plus N-acetyl cysteine had a viability of 47.47 ± 6.82% 
(Figure 27). The use of N-acetyl cysteine at 1 mM did not cause any significant change in 
cellular viability when compared to control cells. 
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Figure 27. Cellular viability evaluated using the LDH leakage assay (% of extracellular 
LDH/total LDH) in differentiated H9c2 cells incubated with 2 μM of MTX and N-acetyl cysteine (NAC), 
an antioxidant and reactive species scavenger at 1 mM and NAC + MTX for 48h. Results are 
presented as mean ± SD of 4 independent experiments (total of 24 wells). Statistical analysis was 
done using the Kruskal–Wallis test, followed by the Dunn’s post hoc test (****p < 0.0001 vs. control; 
$$$$p < 0.0001 vs. NAC 1 mM). 
 
 L-carnitine, a mitochondrial enhancer was not able to revert cell 
death caused by mitoxantrone incubation 
L-carnitine acts as a carrier for fatty acids across the inner mitochondrial membrane 
for subsequent β-oxidation (Zammit et al., 2009). L-carnitine did not cause any significant 
alteration on the cell death caused by the 48h incubation with 2 µM MTX (Figure 28). At 
48h, 2 µM MTX had 53.29 ± 5.67% viability, whereas the condition 2 µM MTX plus L-
carnitine had a viability of 52.83 ± 5.56% (Figure 28). The use of L-carnitine at 2 mg/mL did 
not cause any significant change in cellular viability when compared to control cells. 
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Figure 28. Cellular viability evaluated using the LDH leakage assay (% of extracellular 
LDH/total LDH) in differentiated H9c2 cells incubated with 2 μM of MTX, and L-Carnitine (L-Carn), a 
mitochondrial enhancer at 2 mg/mL and L-Carn + MTX for 48h. Results are presented as mean ± 
SD of 4 independent experiments (total of 24 wells). Statistical analysis was done by using the 
Kruskal–Wallis test, followed by the Dunn’s post hoc test (****p < 0.0001 vs. control; $$$$p < 0.0001 
vs. L-Carnitine 2 mg/mL. 
 
 3-Methyladenine, an autophagy inhibitor, did not inhibit cell 
death caused by incubation with mitoxantrone 
3-Methyladenine was used to assess if autophagy was involved on MTX cytotoxicity. 
3-Methyladenine did not inhibit the cell death caused by the 48h incubation of 2 µM MTX 
(Figure 29). At 48h, 2 µM MTX had 49.40 ± 4.00% viability, whereas the condition 2 µM 
MTX plus 3-methyladenine had a viability of 48.30 ± 2.92% (Figure 29). The use of 3-
methyladenine at 2.5 mM did not cause any significant change in cellular viability when 
compared to vehicle cells. 
 
 
 
Figure 29. Cellular viability evaluated using the LDH leakage assay (% of extracellular 
LDH/total LDH) in differentiated H9c2 cells incubated with 2 μM of MTX, 3-methyladenine (3-MA) 2.5 
mM and 3-MA + MTX for 48h. DMSO (final concentration of 0.1% v/v) was used as vehicle. Results 
are mean ± SD of 4 independent experiments (24 wells). Statistical analysis: Kruskal–Wallis test, 
followed by the Student–Newman–Keuls post hoc test (****p < 0.0001 vs. vehicle; $$$$p < 0.0001 vs. 
3-MA 2.5 mM).  
 
 The 3-methyladenine, an autophagy inhibitor, led to a partial 
protection to the impairment caused in lysossomal uptake by 
mitoxantrone 
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3-Methyladenine is used to inhibit and study the mechanism of autophagy 
(lysosomal self-degradation) and apoptosis (Viola et al., 2012). After 24 and 48h incubation 
with 2 µM MTX, the lysossomal uptake of NR was evaluated. At 24h, 2 µM MTX had 56.14 
± 7.92%, whereas the condition 2 µM MTX plus 3-methyladenine had values of 65.95 ± 
7.37% (Figure 30A). At 48h (Figure 30B), lysossomal function was even more impaired in 
the condition 2 µM MTX. At 48h, the H9c2 cells incubated MTX 2 µM had 22.76 ± 6.77%, 
and 2 µM MTX plus 3-methyladenine had 36.44 ± 9.06% NR ability uptake when compared 
to vehicle cells. 
 
 
 
Figure 30. NR uptake (% of vehicle) in differentiated H9c2 cells incubated with 2 μM of MTX, 
3-methyladenine (3-MA) 2.5 mM and 3-MA + MTX for 24 (A) and 48h (B). DMSO (final concentration 
of 0.1% v/v) was used as vehicle. Results are mean ± SD of 7 independent experiments (42 wells). 
Statistical analysis: Kruskal–Wallis test, followed by the Student–Newman–Keuls post hoc test (****p 
< 0.0001 vs. vehicle; $$$$p < 0.0001 vs. 3-MA 2.5 mM; #p < 0.05 vs. 2 µM).  
 
 The caspase inhibitor, Ac-LETD-CHO, did not inhibit the cell 
death caused by mitoxantrone in H9c2 cells 
Caspase inhibitor (100 µM) did not inhibit the cell death caused by the 48h 
incubation with 2 µM MTX (Figure 31A). At 48h, 2 µM MTX had 49.81 ± 3.43% viability, 
whereas the condition 2 µM MTX plus caspase inhibitor had a viability of 45.19 ± 12.63% 
(Figure 31A). The use of caspase inhibitor at 100 µM did not cause any significant change 
in cellular viability when compared to control cells. 
At 200 µM concentration, the caspase inhibitor also did not protected H9c2 cells 
from the damage caused by MTX (Figure 31B). At 48h, 2 µM MTX had 44.35 ± 6.40% 
viability, whereas the condition 2 µM MTX plus caspase inhibitor (200 µM) had a viability of 
44.74 ± 4.78% (Figure 31B). The use of caspase inhibitor at 200 µM did not cause any 
significant alteration on cellular viability when compared to control cells.  
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Figure 31. Cellular viability evaluated using the LDH leakage assay (% of extracellular 
LDH/total LDH) in differentiated H9c2 cells incubated with 2 μM of MTX, Ac-LETD-CHO 100 µM (A) 
or 200 µM (B) and Ac-LETD-CHO + MTX for 48h. Results are mean ± SD of 4 independent 
experiments (24 wells). Statistical analysis: Kruskal–Wallis test, followed by the Student–Newman–
Keuls post hoc test (****p < 0.0001 vs. control; $$$$p < 0.0001 vs. Ac-LETD-CHO).  
 
 Cycloheximide, a protein synthesis inhibitor, did not inhibit the 
cell death caused by incubation with mitoxantrone 
Cycloheximide (10 µg/mL) did not prevent MTX-induced cytotoxicity in H9c2 cells. 
At the cellular level, cycloheximide blocks the translation of messenger RNA on cytosolic, 
80S ribosomes, but does not inhibit organelle protein synthesis (Obrig et al., 1971). At 48h, 
2 µM MTX had 86.95 ± 5.79%, MTT reduction whereas the condition 2 µM MTX plus 
cycloheximide had 88.04 ± 5.72% MTT reduction ability when compared to control cells 
(Figure 32). Cycloheximide by itself did not cause any cytotoxicity in the time-point and 
concentration tested.  
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Figure 32. Mitochondrial dysfunction evaluated by MTT reduction assay in differentiated 
H9c2 cells incubated with 2 μM of MTX, cycloheximide (Cyc.) 10 µg/mL and Cyc. + MTX for 48h. 
Results are mean ± SD of 3 independent experiments (18 wells). Statistical analysis: Kruskal–Wallis 
test, followed by the Student–Newman–Keuls post hoc test (***p < 0.001; ****p < 0.0001 vs. control; 
$$p < 0.01; $$$$p < 0.0001 vs. cycloheximide 10 µg/mL). 
 
 1-Aminobenzotriazole, a suicide CYP450 inhibitor, did not 
revert the cytotoxicity caused by mitoxantrone 
1-Aminobenzotriazole inhibits CYP450 metabolism (Linder et al., 2009). 1-
Aminobenzotriazole (0.5 mM) did not inhibit cell death caused by the 48h incubation of 2 
µM MTX (Figure 33). At 48h, 2 µM MTX had 48.39 ± 6.49% viability, whereas the condition 
2 µM MTX plus 1-aminobenzotriazole showed a viability of 46.69 ± 4.61% (Figure 33A). 
After 48h incubation, the lysossomal uptake of NR was evaluated. At 48h, the H9c2 cells 
incubated MTX 2 µM had 34.73 ± 4.69%, 2 µM MTX plus 1-aminobenzotriazole had 33.09 
± 5.72% NR ability when compared to control cells (Figure 33B). 1-Aminobenzotriazole by 
itself did not cause any cytotoxicity in the time-point and concentration tested. 
 
 
 
Figure 33. Cellular viability evaluated using the LDH leakage assay (% of extracellular 
LDH/total LDH) (A) in differentiated H9c2 cells incubated with 2 μM of MTX, 1-aminobenzotriazole 
(1-abtz) 0.5 mM and 1-abtz + MTX for 48h. NR uptake (% control) (B) in differentiated H9c2 cells 
incubated with 2 μM of MTX, 1-abtz and 1-abtz + MTX for 48h. Results are mean ± SD of 6 
independent experiments (36 wells). Statistical analysis were performed using Anova test, followed 
by the Tukey’s post hoc test (****p < 0.0001 vs. control; $$$$p < 0.0001 vs. 1-abtz 0.5 mM). 
 
 Metyrapone, a competitive CYP450 inhibitor, did not inhibit the 
cytotoxicity caused by mitoxantrone in H9c2 cells 
Metyrapone is a competitive CYP450 inhibitor (Sampath-Kumar et al., 1997) and it 
did not inhibit the cytotoxicity caused by the 48h incubation of 2 µM MTX (Figure 34). At 
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48h, the H9c2 cells incubated MTX 2 µM had 64.96 ± 5.88%, 2 µM MTX plus metyrapone 
had a MTT reduction of 58.81 ± 6.46% when compared to control cells (Figure 34A). After 
48h incubation, the lysossomal uptake of NR was evaluated. At 48h, the H9c2 cells 
incubated MTX 2 µM had 37.08 ± 13.34%, 2 µM mitoxantrone plus metyrapone had 34.84 
± 19.54% NR ability when compared to control cells (Figure 34B). 
 
 
 
Figure 34. Mitochondrial dysfunction evaluated by MTT reduction assay (A) in differentiated 
H9c2 cells incubated with 2 μM of MTX, metyrapone (MTP) 0.5 mM and MTP + MTX for 48h. Results 
are presented as mean ± SD of 5 independent experiments (30 wells). Statistical analysis was 
performed using Anova test, followed by the Tukey’s post hoc test (****p < 0.0001 vs. vehicle; $$$$p 
< 0.0001 vs. MTP; &&&&p < 0.0001 vs. 2 µM MTX. NR uptake (% of vehicle) (B) in differentiated H9c2 
cells incubated with 2 μM of MTX, MTP and MTP + MTX for 48h. Results are mean ± SD of 4 
independent experiments (24 wells). Statistical analysis: Kruskal–Wallis test, followed by the 
Student–Newman–Keuls post hoc test (****p < 0.0001 vs. vehicle; $$$$p < 0.0001 vs. MTP). DMSO 
(final concentration of 0.1% v/v) was used as vehicle. 
 
 Mitoxantrone was able to alter the ATP levels in H9c2 cells in a 
concentration-independent manner 
To understand if MTX has effects in cellular energetics, intracellular ATP levels were 
measured in H9c2 cell exposed to MTX for 24h. ATP intracellular levels after MTX 
incubation were assessed through the bioluminescence assay. MTX increased the ATP 
levels in the time point tested, as shown in the Figure 35: after 24h incubation with MTX (2 
and 5 μM), the ATP intracellular levels were about 41.10 ± 5.65 nmol/mg protein and 44.63 
± 8.80 nmol/mg protein, respectively, compared to 16.87 ± 1.54 nmol/mg protein for the 
control group. 
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Figure 35. ATP levels in differentiated H9c2 cells incubated with 2 and 5 μM of MTX for 24h. 
Results, in nmol/mg protein, are presented as mean ± SD of 6 independent experiments. Statistical 
analysis was performed using Anova test, followed by the Tukey’s post hoc test (****p < 0.0001 vs. 
control). 
 
4.5. Toxicological evaluation of naphthoquinoxaline  
 Microscopic evaluation of naphthoquinoxaline incubated H9c2 
cells 
Cells were morphologically assessed after 24h exposure to NAPHT. H9c2 cells were 
incubated with NAPHT (2 and 5 μM), as described in the Methods section. Phase-contrast 
microscopy and Hoescht staining were used to describe the microscopic features 
associated with NAPHT-induced H9c2 cytotoxicity. Phase-contrast microscopy, after 24h 
incubation, revealed cell injury, with intensifying features with increasing concentrations, 
namely cytoplasmatic injury (Figure 36). The decrease in cell number was observed (Figure 
36C and 36F), but the decrease was lower in comparison with the results of MTX. No 
apoptotic nucleus were observed. At 48h, the cell injury was increased in NAPHT-incubated 
cells (data not shown).  
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Figure 36. Fluorescence microscopy (Hoechst 33258 staining) (A, B, C), and phase contrast 
microscopy (D, E, F) images of differentiated H9c2 cells after incubation with 2 and 5 μM of NAPHT 
for 24h. DMSO (final concentration of 0.1% v/v) was used as vehicle (A and D), NAPHT 2 μM (B and 
E), and NAPHT 5 μM (C and F). Images are representative of three independent experiments (scale 
bar 100 μm). 
 
Ethidium bromide/ acridine orange staining was also used for evaluate NAPHT 
effects on H9c2 cells. Through this method, living cells appear with a regular-sized green 
fluorescent nucleus, as shown in vehicle incubated H9c2 cells in Figure 37A. The cells 
incubated with NAPHT show with green nucleus, although with signs of cytoplasmatic injury 
(Figure 37B and C). 
 
 
 
Figure 37. Ethidium bromide and acridine orange (A, B, C) images of differentiated H9c2 
cells after incubation with 2 and 5 μM of NAPHT for 24h. DMSO (final concentration of 0.1% v/v) was 
used as vehicle (A), NAPHT 2 μM (B), NAPHT 5 μM (C). Images are representative of three 
independent experiments (scale bar 100 μm). 
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Assessment of mitochondrial membrane potential in differentiated H9c2 cells 
incubated with 2 μM of NAPHT (B) and 5 μM of NAPHT (C) for 12h (Figure 38) was also 
performed. Lower levels of fluorescence resulting from NAPHT treatment were observed, 
suggesting that the depolarization of mitochondrial membrane potential at 12h occurred 
after incubation with NAPHT. This depolarization effect seems to be dose dependent 
(Figure 38). 
 
 
 
Figure 38. Images of mitochondrial transmembrane potential of differentiated H9c2 cells after 
incubation with 2 and 5 μM of NAPHT for 12h (A, B, C). DMSO (final concentration of 0.1% v/v) was 
used as vehicle (A), NAPHT 2 μM (B), NAPHT 5 μM (C). Images are representative of three 
independent experiments (scale bar 100 μm). 
 
 Naphthoquinoxaline caused a time- and concentration-
dependent mitochondrial dysfunction 
The ability of NAPHT to interfere with MTT reduction was evaluated at 2 time-points 
(24 and 48h) and with several concentrations (1 to 5 µM). At 24h (Figure 39A), NAPHT at 
concentration 2 and 5 µM caused cytotoxicity when compared to control cells. At 48h, 
(Figure 39A) NAPHT at all the concentrations tested caused significant cytotoxicity when 
compared to vehicle cells, being the highest concentration tested (5 µM) able to decrease 
the levels of MTT reduction to 82.49 ± 4.05% when compared to vehicle cells (100 ± 3.85%). 
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Figure 39. Mitochondrial dysfunction evaluated by MTT reduction in differentiated H9c2 cells 
incubated with 1, 2 and 5 μM of NAPHT for 24 (A) and 48h (B). DMSO (final concentration of 0.1% 
v/v) was used as vehicle. Results are presented as mean ± SD of 6 independent experiments (total 
of 35 - 36 wells). Statistical analysis were performed using the Anova test, followed by the Tukey’s 
post hoc test (*p < 0.05, **p < 0.01, ***p < 0.001 vs. vehicle; ##p < 0.01, ####p < 0.0001 vs. 1 µM; $$$$p 
< 0.0001 vs. 2 µM). 
 
 Naphthoquinoxaline was able to cause significant loss of 
membrane integrity  
The ability of NAPHT to cause cell death was tested at 2 time-points (24 and 48h) 
and with several concentrations (1 to 5 µM). At 24h (Figure 40A), all the concentrations of 
NAPHT (1, 2 and 5 µM) tested caused significant cellular membrane integrity loss when 
compared to control cells. In Figure 40B, the data obtained after the 48h incubation of 
NAPHT in H9c2 differentiated cells is observed. NAPHT at 48h caused a significant 
decrease in cellular integrity, being observed that at 2 µM NAPHT the viability was 73.02 ± 
2.86% and at 5 µM the viability was 52.07 ± 6.83%, when compared with vehicle cells (81.91 
± 1.89%).  
 
 
 
Figure 40. Cellular viability evaluated using the LDH leakage assay (% of extracellular 
LDH/total LDH) in differentiated H9c2 cells incubated with 1, 2 and 5 μM of NAPHT for 24 (A) and 
48h (B). DMSO (final concentration of 0.1% v/v) was used as vehicle. Results are presented as mean 
± SD of 6 independent experiments (total of 35 - 36 wells). Statistical analysis was performed at 24h 
using the Kruskal–Wallis test, followed by the Student–Newman–Keuls post hoc test. For 48h, the 
Anova test, followed by the Tukey’s post hoc test, was used (***p < 0.001, ****p < 0.0001 vs. vehicle; 
###p < 0.001, ####p < 0.0001 vs. 1 µM; $$p < 0.01, $$$$p < 0.0001 vs. 2 µM). 
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 Naphthoquinoxaline caused a significant lysosome uptake 
dysfunction in H9c2 differentiated cells 
After 24 and 48h incubation with several concentrations of NAPHT (1 to 5 µM), the 
lysossomal uptake of NR was evaluated. At 24h (Figure 41A), only the highest 
concentrations of NAPHT (2 and 5 µM) caused a substantial impairment of lysossomal 
uptake of NR when compared to control cells. At 48h (Figure 41B) the H9c2 cells incubated 
with NAPHT 2 µM had 88.82 ± 5.53% of NR uptake, while 5 µM showed values of 68.83 ± 
6.28% NR incorporation when compared to vehicle cells (100.00 ± 6.18%).  
 
 
 
Figure 41. NR uptake (% of vehicle) in differentiated H9c2 cells incubated with 1, 2 and 5 μM 
of NAPHT for 24 (A) and 48h (B). DMSO (final concentration of 0.1% v/v) was used as vehicle. 
Results are presented as mean ± SD of 5 independent experiments (total of 30 wells). Statistical 
analysis was performed using the Anova test, followed by the Tukey’s post hoc test for analysis at 
24h and Kruskal–Wallis test, followed by the Student–Newman–Keuls post hoc test, for analysis at 
48h (**p < 0.01, ****p < 0.0001 vs. vehicle; #p < 0.05, ####p < 0.0001 vs. 1 µM; $$p < 0.01, $$$$p < 
0.0001 vs. 2 µM). 
 
 N-acetyl cysteine incubation increased cell death caused by 
naphthoquinoxaline 
N-acetyl cysteine, a glutathione precursor and reactive species scavenger 
(Avantaggiato et al., 2014), at 1 mM concentration was used in H9c2 cells. N-acetyl cysteine 
increased cell death caused by 2 µM NAPHT (Figure 42). At 48h, 2 µM NAPHT had 74.09 
± 2.50% viability, whereas in the condition 2 µM NAPHT plus N-acetyl cysteine the viability 
observed was 68.16 ± 3.26% (Figure 42). The use of N-acetyl cysteine at 1 mM did not 
cause significant change in cellular viability when compared to vehicle cells.  
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Figure 42. Cellular viability at 48h evaluated using the LDH leakage assay (% of extracellular 
LDH/total LDH) in differentiated H9c2 cells incubated with 2 μM of NAPHT and N-acetyl cysteine 
(NAC), an antioxidant, at 1 mM. DMSO (final concentration of 0.1% v/v) was used as vehicle. Results 
are presented as mean ± SD of 4 independent experiments (total of 24 wells). Statistical analysis 
was performed using the Anova test, followed by the Tukey’s post hoc test (****p < 0.0001 vs. vehicle; 
$$$$p < 0.0001 vs. NAC; &&&&p < 0.0001 vs. 2 µM NAPHT). 
 
 3-Methyladenine, an autophagy inhibitor, caused a partial 
protection to the damage caused by naphthoquinoxaline 
After 48h incubation with 2 µM NAPHT, the lysossomal uptake of NR was evaluated. 
At 48h, 2 µM NAPHT showed values of 88.26 ± 6.93%, whereas the condition 2 µM NAPHT 
plus 3-methyladenine had the values of 94.24 ± 7.91% (Figure 43). Thus, 3-methyladenine 
caused a partial protection to the effects caused by NAPHT. 
 
 
 
Figure 43. NR uptake (% of vehicle) in differentiated H9c2 cells incubated with 2 μM of 
NAPHT, 3-methyladenine (3-MA) 2.5 mM and 3-MA + NAPHT for 48h. DMSO (final concentration of 
0.1% v/v) was used as vehicle. Results are mean ± SD of 5 independent experiments (30 wells). 
Statistical analysis was performed using the Anova test, followed by the Tukey’s post hoc test (**p < 
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0.01, ****p < 0.0001 vs. vehicle; $$$p < 0.001, $$$$p < 0.0001 vs. 3-MA 2.5 mM; &&p < 0.01 vs. 2 µM 
NAPHT). 
 
 Naphthoquinoxaline did not cause any significant alteration on 
ATP levels at an early time-point 
To understand if NAPHT has effects in cellular energetics, intracellular ATP levels 
were measured in H9c2 cell exposed to NAPHT for 24h. In the NAPHT tested concentration, 
and time point (24h), no significance changes were detected, as shown in the Figure 44. 
After the 24h incubation with NAPHT (2 and 5 μM), the ATP intracellular levels were about 
14.94 ± 4.38 nmol/mg protein and 16.74 ± 4.21 nmol/mg protein, respectively, compared to 
14.24 ± 3.48 nmol/mg protein for the vehicle group. 
 
 
 
Figure 44. ATP levels in differentiated H9c2 cells incubated with 2 and 5 μM NAPHT for 24h. 
DMSO (final concentration of 0.1% v/v) was used as vehicle. Results, in nmol/mg protein are 
presented as mean ± SD of 6 independent experiments.  
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Xenobiotics that cause heart damage may have a part of their toxicity resulting from 
metabolization. This chemical change is mainly catalysed by enzymes, and usually favours 
the increase of hydrophilicity of parental xenobiotics. The majority of the metabolism in the 
body occurs in the liver, and the metabolites formed can reach the heart due to the 
distribution via blood stream. Moreover, the heart also has metabolizing enzymes, therefore 
in loco it generates metabolites that may cause cardiac toxicity (Wormhoudt et al., 1999). 
Several anticancer drugs can lead to cardiotoxicity. Some drugs, like DOX and 
cyclophosphamide, are shown to be cardiotoxic through their metabolites (Costa et al., 
2013). Other anticancer drugs are scarcely studied regarding the cardiotoxicity of their 
metabolites. 
 
5.1. Synthesis and purification of the mitoxantrone metabolite 
naphthoquinoxaline 
The full characterization of the metabolic profile and the elucidation of the 
metabolites structure in new chemical entities are often not completed during clinical 
development or even after the drugs’ introduction into the market (Fura et al., 2004). It is 
also often difficult to predict a priori whether after metabolization a certain compound could 
form a toxic or pharmacologically active metabolite. The degree of contribution of active 
metabolites to the overall observed therapeutic or toxic effects needs further study, but the 
rapid chemical synthesis of metabolites by traditional methods is often challenging (Fura et 
al., 2004). 
In this thesis, the synthesis of MTX metabolites was accomplished by the HRP 
catalysed H2O2 oxidation (Figure 10). Several derivatives were observed by 
chromatographic analysis of the crude product and two purified derivatives were isolated 
and identified as NAPHT, an already reported metabolite of MTX, and a newly isolated 
derivative, NAPHTdi. The enzymatically catalysed oxidation of MTX by HRP/H2O2 has 
already been demonstrated in other works (Reszka et al., 1986, Kolodziejczyk et al., 1988, 
Bruck and Bruck, 2011). In those works, the isolation of the metabolite NAPTH was 
achieved and it was partially characterized by 13C NMR and liquid chromatography-mass 
spectrometry. Herein, the isolation and structure characterization of NAPHT was 
accomplished and additionally the isolation of a possible oxidation product of MTX, 
NAPHTdi, was achieved for the first time.  
5. Discussion and conclusions 
114 
In the study by Blanz et al., NAPHT metabolite was isolated by preparative HPLC 
from the urine of a patient and it was characterized by tandem mass spectrometry and UV-
visible spectroscopy (Blanz et al., 1991b). Moreover, two studies in cell systems suggest 
that NAPHT may contribute to the cytotoxic activity of MTX (Duthie and Grant, 1989, Mewes 
et al., 1993). 
The proposed mechanism for the formation of NAPHT and NAPHTdi (seen in Figure 
45) (Blanz et al., 1991b) established the reaction to proceed via a two-electron oxidation of 
the phenylenediamine substructure I to the formation of the highly reactive quinone II. The 
nonprotonated form IV of the equilibrium reacts by an intramolecular attack of the basic 
amino group of the side chain with the electrophilic centre at C-6 of MTX radical cation. 
Subsequent oxidation of the cyclized radical V led to the formation of NAPHT. As the 
reaction progressed, further oxidation of the NAPHT side-chains occurred, yielding the 
dicarboxylic acid derivative NAPHTdi.  
 
 
 
Figure 45. Proposed mechanism for the formation of NAPHT and NAPHTdi after the 
oxidation of MTX. Adapted from Blanz et al., 1991b. 
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The NAPHT and other metabolites resulting from oxidation of MTX are not normally 
purified after synthesis. For example, in the study of Bruck et al., the crude product of the 
HRP/H2O2 catalysed oxidation was used for the steady-state spectrokinetic and HPLC-MS 
analysis without further purification (Bruck and Bruck, 2011). Herein, with the purification 
methods used allowed to obtain a high purity NAPHT metabolite that allowed further 
toxicological evaluation. Nevertheless, the amount of NAPHTdi obtained did not allow 
further in vitro studies and the unequivocal structure characterization. 13C NMR analysis 
should be considered in a future work for its full chemical characterization. This compound 
has already been previously proposed by UV analysis to be formed with the HRP catalysed 
H2O2 oxidation (Bruck and Harvey, 2003). In this thesis, NAPHTdi was first time isolated 
and characterized.  
 
5.2. Decreased foetal bovine serum and the addition of retinoic acid 
to H9c2 cells caused cell differentiation  
The H9c2 myoblast cell line, originated from rat ventricular tissue, has been used in 
vitro as a model for skeletal and cardiac muscle due to the morphological features and 
electrical/hormonal signalling properties of these cells (Kimes and Brandt, 1976, Hescheler 
et al., 1991).  
H9c2 cells show electrophysiological and biochemical properties of both skeletal and 
cardiac tissues, including depolarization in response to acetylcholine (Kimes and Brandt, 
1976), and rapid activation of calcium currents through L-type channels (Hescheler et al., 
1991, Mejia-Alvarez et al., 1994, Wang et al., 1999). An interesting feature of this cell line 
is its ability to differentiate from mono-nucleated myoblasts to myotubes upon reduction of 
serum concentration (Hescheler et al., 1991). With myotube formation the expression of 
myogenic transcription factors (Chun et al., 2000) and calcium channel proteins also occurs 
(Menard et al., 1999). 
Despite the wide use of the H9c2 cell line in the undifferentiated state, a cardiac-like 
phenotype can be obtained after differentiation in a low FBS (1%) and 10 nM RA -
supplemented media. Because the adult heart tissue is composed mainly by differentiated 
cardiomyocytes, toxicological studies can have different outcomes depending on the 
developmental state of the biological model used (Branco et al., 2011). In the study by 
Menard et al., the cells were cultured in DMEM supplemented with 1% foetal calf serum 
(replaced every 2 days) and RA (Menard et al., 1999). RA-treated cells exhibited 
morphological changes with rather large and rounded cells. The treatment of H9c2 cells 
with RA maintained their cardiac phenotype and inhibited myogenic differentiation of those 
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cells (Menard et al., 1999). In the study by Branco et al., they investigated whether RA-
driven cell differentiation results in the increase of specific markers for cardiac cells (Branco 
et al., 2011). Higher protein content of phosphorylated-troponin I, cardiac troponin T and 
ventricular myosin light chain were observed when H9c2 cells were differentiated in a low 
serum media supplemented with RA, confirming that this treatment drives H9c2 cells to a 
cardiac-like phenotype (Branco et al., 2011).  
In the study by Ruiz et al., they observed morphological alterations in H9c2 cells, 
after the induction of differentiation by serum reduction and RA supplementation. The 
results obtained confirm that H9c2 myoblasts fuse and form multinucleated cells (Ruiz et 
al., 2012). The differentiation process initiates a cell cycle arrest, which decreases cellular 
proliferation and alters their morphological features (Menard et al., 1999, Branco et al., 
2011), as we found with our results. Cellular proliferation depends on the existence of 
growth factors in the culture media, hence it is expected that the reduction in the 
concentration of those factors will induce cell growth arrest, whereas the addition of RA 
drives the differentiation towards a cardiac phenotype (Menard et al., 1999, Branco et al., 
2011, Pereira et al., 2011, Ruiz et al., 2012).  
In our work, the differentiation protocol was conducted with RA 10 nM and 1% FBS 
for 7 days. There were substantial differences between undifferentiated cells and 
differentiated cells, which are illustrated in Figure 19. The differentiation protocol 
dramatically reduced cell division as in study the Branco et al. and in the study the Ruiz et 
al. (Branco et al., 2011, Ruiz et al., 2012). In fact, cellular density was substantially higher 
in undifferentiated cells maintained for 7 days as seen with Hoescht 33258 staining. Also, 
while accompanying inhibition of cell division, the cell bodies of differentiated cells became 
smaller and fusiform when compared to undifferentiated cells, which exhibit a large and flat 
cell body (Figure 19). This differentiation model becomes a more reliable cardiac model 
leading to a better extrapolation of results. 
 
5.3. Cytotoxicity effects of mitoxantrone in differentiated H9c2 cells  
Cytotoxicity assays are widely used as in vitro toxicology studies. The LDH leakage 
assay, the NR and the MTT assays are the most common assays employed for the 
detection of cytotoxicity following exposure to potentially toxic substances (Fotakis and 
Timbrell, 2006). The LDH leakage assay is based on the measurement of LDH activity in 
the extracellular medium. The loss of intracellular LDH and its release into the culture 
medium is an indicator of irreversible cell death due to cell membrane damage. The MTT 
assay is another assay often used to determine cytotoxicity. MTT is a water soluble 
tetrazolium salt, which is converted to an insoluble purple formazan by the cleavage of the 
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tetrazolium ring mainly by succinate dehydrogenase within the mitochondria (Fotakis and 
Timbrell, 2006, Costa et al., 2009). The formazan product formed within the cells is 
impermeable to the cell membranes and therefore it accumulates in healthy cells. The NR 
assay is also used to measure cytotoxicity. Living cells take up the NR, which is mainly 
concentrated within the lysosomes of cells (Fotakis and Timbrell, 2006). 
In this thesis, the three cytotoxicity assays were employed to assess MTX toxicity in 
vitro. The results obtained complemented themselves and allowed a better characterization 
of the mechanisms involved, because of the different nature of each assay. After the 
differentiation protocol, cells were incubated with MTX (0.01 µM to 5 µM) for two time-points 
(24 and 48h), where the cytotoxicity tests (LDH assay, MTT assay and the NR uptake 
assays) were performed. The MTX cytotoxicity was demonstrated at different 
concentrations and time points, through the decline in the cell viability observed in the LDH 
leakage assay (Figure 24), the decrease in the MTT reduction activity (Figure 23) and 
through a significant impairment of NR lysossomal uptake (Figure 25). The lowest MTX 
concentrations (0.01 and 0.1 µM) did not cause cytotoxicity in H9c2 cells. However, for the 
highest concentrations (1, 2, and 5 µM), cytotoxicity was time- and concentration-dependent 
in all assays, being the NR assay more sensitive for the MTX toxic effects in H9c2 
differentiated cells.  
In the work by Rossato and co-workers, they tested seven MTX concentrations (10 
and 100 nM, and 1, 5, 10, 50 and 100 μM) and four time points were selected (24, 48, 72, 
and 96h), using the undifferentiated H9c2 cells as cellular model. Rossato et al. observed 
that MTX-induced cytotoxicity was time- and concentration-dependent in the LDH leakage 
assay and MTT reduction assay (Rossato et al., 2013b). When comparing our results with 
the results obtained in the study mentioned above, we observed that at 24h, in the study by 
Rossato, 1 μM MTX did not led to a significant cell death, whereas in our study the same 
concentration caused significant decrease in cells’ viability (64.08 ± 8.26%). In the present 
thesis, the concentration of 5 μM after the 48h incubation also induced a higher cell death 
(27.98 ± 9.92%) when compared to the mentioned work. The differentiated H9c2 cells seem 
more sensitive to the MTX effects than the undifferentiated H9c2 cells used in the study by 
Rossato et al. In fact, despite the lower cellular division in differentiated cells, MTX appears 
to be more toxic in the cells with the cardiac phenotype, thus revealing that MTX does not 
act only on cellular division. In the MTT reduction test, herein a significant cytotoxicity was 
observed, however lower than in the study of Rossato et al. (Rossato et al., 2013b). In this 
thesis, the concentration of 0.1 µM after a 24h incubation already caused significant 
cytotoxicity (93.74 ± 10.22%) when compared to control cells (100.00 ± 4.99%), being the 
highest dose tested (5 µM) able to decrease the levels of MTT reduction to 85.99 ± 8.52% 
when compared to control cells. At 48h, the cytotoxicity elicited was even higher, when 
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compared to control cells and the earlier time point. In the work by Rossato et al., either at 
24 as after the 48h incubation, the MTT reduction was significantly lower in 1 and 5 µM 
MTX-incubated H9c2 undifferentiated cells (Rossato et al., 2013b) than in the results of this 
thesis. These differences are possibly the result of the differentiation. Our cells are 
differentiated having lower proliferation rate, whereas in the work by Rossato and co-
workers the cells are rapidly dividing. The values obtained in the MTT reduction assay are 
the result of a ratio to control cells and the control wells of undifferentiated cells have higher 
metabolization ability. In the study by Rossato and colleagues, the results suggested that 
mitochondrial effects anticipate cellular membrane rupture for MTX toxicity, because they 
observed that the toxic effects occurred earlier in the MTT reduction assay than in the LDH 
leakage assay in all times tested (Rossato et al., 2013b). In the present work, the MTT test 
also seems to be very sensitive to exposure of low concentrations of MTX and earlier time 
points. 
To the best of our knowledge, there are no studies in the literature for the NR assay 
in H9c2 cell incubated with MTX. This assay was for the first performed for MTX and is the 
most sensitive for the MTX toxic effects in H9c2 differentiated cells. 
 
5.4. Evaluation of several pharmacological active molecules towards 
the cytotoxic effects of mitoxantrone 
Several pharmacological active molecules were used to elucidate the mechanisms 
involved in MTX-induced cardiotoxicity, namely N-acetyl cysteine, buthionine sulphoximine, 
cycloheximide, and L-carnitine. 
Reactive oxygen species are created during the process of mitochondrial oxidative 
energy generation, among other processes (Costa et al., 2011). Cellular damage occurs 
when reactive oxygen species production exceeds the detoxifying ability of antioxidant 
enzymes or cofactors. N-acetyl cysteine has antioxidant proprieties and is the precursor of 
the amino acid cysteine, which is one of the three components of glutathione (gamma-
glutamyl-cysteinyl-glycine), the major antioxidant of the body that works in both intra and 
extracellular compartments (Avantaggiato et al., 2014). Buthionine sulphoximine induces 
oxidative stress by irreversibly inhibiting gamma-glutamylcysteine synthetase, an essential 
enzyme for the synthesis of glutathione (Reliene and Schiestl, 2006).  
In our study in differentiated H9c2 cells, the pre-incubation with the radical 
scavenger N-acetyl cysteine (1 mM) (Figure 27) or with the inhibitor of gamma-
glutamylcysteine synthetase, buthionine sulphoximine (50 μM), (Figure 26) did not alter any 
of the cytotoxic effects observed with the MTX (2 μM) incubation for 48h in the LDH assay. 
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The lack of protective effects of N-acetyl cysteine or of increased toxicity by buthionine 
sulphoximine in the present study may result in the fact that other mechanisms involved in 
MTX toxicity exert a major role when compared to oxidative stress or glutathione pathways. 
Rossato et al. tested N-acetyl cysteine (1 mM) in other experimental conditions: 
undifferentiated cells H9c2 were incubated with 100 nM and 1 μM MTX for 96h, being the 
MTT reduction test used for the evaluation. Consistently, the pre-incubation with the radical 
scavenger N-acetyl cysteine did not prevent any of the cytotoxic effects observed with the 
MTX incubation for 96h in the MTT reduction test (Rossato et al., 2013b). Ferreira et al. pre-
treated SH-SY5Y differentiated cells with buthionine sulphoximine (25 μM) before adding 3, 
4- methylenedioxymethamphetamine or metabolites (100, 200, 400 and 800 μM), for 24 
and 48h, also using the MTT reduction test (Ferreira et al., 2013). In the study by Ferreira 
et al., they observed that the buthionine sulphoximine (25 μM) after 48h of exposure was 
not cytotoxic as evaluated by the MTT test and by the cellular protein content, but N-methyl-
α-methyldopamine incubation in buthionine sulphoximine pre-treated cells for 48h 
increased the toxicity of this 3, 4- methylenedioxymethamphetamine metabolite (Ferreira et 
al., 2013). The authors verified in SH-SY5Y cells that the glutathione pathways were 
involved in the toxicity of that methylenedioxymethamphetamine metabolite (Ferreira et al., 
2013). To the best of our knowledge, there are no studies with differentiated H9c2 cells and 
MTX with buthionine sulphoximine or N-acetyl cysteine. 
Our study in differentiated H9c2 cells showed that with mitochondrial enhancer L-
carnitine (2 mg/mL) was not able to prevent any of the cytotoxic effects observed with the 
MTX (2 μM) incubation for 48h in the LDH assay (Figure 28). L-carnitine is considered a 
mitochondrial enhancer by improving the mitochondrial β-oxidation of fatty acids, the trans-
esterification/excretion of acyl-coenzyme A esters, the oxidation of α-ketoacids, and by the 
removal of toxic acyl carnitine ester from the mitochondria (Zammit et al., 2009). The work 
of Rossato et al. evidenced the early MTX-induced energetic crisis as a possible key factor 
in the cell injury, however Rossato et al. showed that L-carnitine (1 mM) did not prevent any 
of the cytotoxic effects observed with the MTX (100 nM and 1 μM) incubation for 96h in the 
MTT reduction test in undifferentiated cells H9c2 (Rossato et al., 2013b). 
Our study in differentiated H9c2 cells, the pre-incubation with cycloheximide (10 
μg/mL) did not prevent any of the cytotoxic effects observed with the MTX (2 μM) incubation 
for 48h in the LDH assay (Figure 32). Protein synthesis is involved in many processes of 
programmed and non-programmed cell death (Martins et al., 2013), but it does not seem to 
have a major role in these experimental conditions. 
 
5.5. Mechanisms of cell death induced by mitoxantrone 
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Cell death has been generally subdivided into several categories: apoptosis (type I), 
autophagy (type II), and necrosis (type III) (Lockshin and Zakeri, 2004). Cell death can be 
classified according to their morphological appearance (apoptosis, necrosis, autophagy), 
criteria based on enzymes (with or without the involvement of nucleases or different classes 
of proteases, such as caspases, cathepsins and glutaminases), functional aspects 
(programmed or accidental, physiological or pathological) or immunological characteristics 
(immunogenic or non-immunogenic) (Galluzzi et al., 2007). In multicellular organisms, cells 
that are no longer needed or that are a threat to the organism are destroyed by a tightly 
regulated cell suicide process known as programmed cell death, or apoptosis (Alberts et 
al., 2002). Apoptosis is characterized by chromatin condensation, DNA fragmentation, and 
possible activation and not activation of caspases (Klionsky, 2007). Caspases play a central 
role in the transduction of death receptors apoptotic signals. There are two types of 
caspases: initiator caspases, caspase 2, 8, 9, and 10, and effector caspases, caspase 3, 6, 
and 7 (Denault et al., 2007).  
There are two distinct molecular signalling pathways that lead to cell death by 
apoptosis, the intrinsic pathway or mitochondrial and the extrinsic pathway or via the death 
receptor (de Bruin and Medema, 2008). Mitochondrial changes, including variations in 
mitochondrial membrane potential, can be key events during drug-induced apoptosis. The 
permeabilization the mitochondrial membrane induces the formation of pores through which 
small molecules are released from their intermembrane space (de Bruin and Medema, 
2008). 
Autophagy is now recognized as an important process involved in different human 
pathologies, such as neurodegenerative diseases, aging, and cancer (Klionsky, 2007, 
Rubinsztein et al., 2007). Autophagy is characterized by the formation of autophagic 
vacuoles in the cytoplasm of cells that are dying (Galluzzi et al., 2007) and is a general term 
for the degradation of cytoplasmatic components within lysosomes (Mizushima, 2007).  
Necrosis is a type of cell death where the cell rapidly loses the integrity of its 
membrane, venting the intracellular contents (Galluzzi et al., 2007). Unlike apoptosis, 
necrosis has been considered as an uncontrolled cell death, leading to irreversible cell 
damage. Necrosis involves dramatic changes in the mitochondria, including mitochondrial 
depolarization, ATP depletion, generation of reactive oxygen species, loss of calcium 
homeostasis and causes vacuolation, loss of membrane integrity, cell swelling followed by 
complete lysis without vesicle formation and disintegration of organelles (de Bruin and 
Medema, 2008). 
Mechanisms of cell death induced by MTX and reported in the literature are: 
apoptosis at lower concentrations (below 20 pg/mL) and necrosis at higher concentrations 
(exceed 20 ng/mL) (Neuhaus et al., 2006). Signals of apoptosis were already described 
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after 24 and 48h of MTX (1.60 μM) incubation in the undifferentiated H9c2 cells (Kluza et 
al., 2004). Moreover, Rossato et al. showed that in undifferentiated H9c2 cells, the 
incubation of 100 nM and 1 μM MTX, for 24h, caused an increase in caspase-3 activity 
(Rossato et al., 2013b). 
To explore the role of apoptosis, the cells H9c2 were incubated in the presence of a 
caspase 8 and 9 inhibitor (100 and 200 μM), as described in the Methods section. The 
caspase inhibitor (caspase 8 and 9, at 100 or 200 µM) did not prevent cytotoxicity. 
Microscopic evaluation, Hoechst and ethidium bromide/acridine orange staining showed no 
signs of apoptosis, namely condensed and pyknotic nuclei. But that does not eliminate the 
possibility that in shorter incubation times, apoptosis may occur. Apoptosis is characterized 
by plasma membrane and mitochondrial alterations, dilation of the endoplasmic reticulum, 
fatty degeneration and nuclear changes (Kumar, 2010). Mitochondrial changes, including 
variations in mitochondrial membrane potential, are the key events during drug-induced 
apoptosis. In fact, in this thesis, lower levels of mitochondrial potential membrane resulting 
from MTX treatment were observed, suggesting the depolarization of mitochondrial 
membrane potential at 12h. This depolarization effect seems to be dose dependent (Figure 
22). Rossato et al. showed that MTX (100 nM and 1 μM) caused hyperpolarization of the 
mitochondrial membrane potential after 24, 48, and 96h of MTX incubation in 
undifferentiated H9c2 cells (Rossato et al., 2013b). The method used by Rossato to 
evaluate mitochondrial potential membrane was flow cytometry analysis. The mitochondrial 
hyperpolarization drives more calcium into the mitochondria matrix and impaired electron 
chain mitochondrial activity (Rossato et al., 2013b). In our study, the method used to 
evaluate membrane potential and incubation-time and -concentration were different. The 
main signs of apoptosis in MTX-treated H9c2 cells are rapid release of the mitochondrial 
proteins apoptosis-inducing factor and cytochrome c into the cytosol (Kluza et al., 2004). 
Kluza et al. observed that MTX-treated H9c2 cells (1.60 μM) for 24h caused a decreased 
in mitochondrial transmembrane potential by cytofluorometric analysis (Kluza et al., 2004). 
In this thesis, the loss of mitochondrial potential membrane may be an early event 
in the apoptotic process. However, this loss of mitochondrial potential membrane (decrease 
levels of fluorescence resulting from MTX treatment) may not be an early requirement for 
apoptosis, but may be a consequence of early apoptotic-signalling pathway. 
To explore the role of autophagy in the cytotoxicity induced by MTX (2 μM), 
differentiated H9c2 cells were incubated in the presence of an autophagy inhibitor, 3-
methyladenine (2.5 mM). The NR test was the most sensitive test for MTX cytotoxicity which 
could indicate that lysossomal damage could be a triggering factor for MTX-induced 
damage (Figure 25). The autophagy inhibitor (3-methyladenine) partially protected against 
MTX-induced cytotoxicity. The use of 3-methyladenine was performed with MTX for the first 
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time (Figure 30). The 3-methyladenine led to a partial protection in the NR test (Figure 30), 
which was not observed in the LDH assay (Figure 29), thus demonstrating that other 
mechanisms may be involved in MTX-membrane damage. 
 
5.6. Evaluation of ATP levels and mitochondrial transmembrane 
potential of mitoxantrone   
To understand if MTX has any effects on cellular energetics, intracellular ATP levels 
were assessed through the bioluminescence test. In our study, levels of ATP increased with 
incubation of MTX at 24h in differentiated H9c2 cells (Figure 35). In other models results 
are different. Recently, Rossato et al. showed that MTX (100 nM and 1 μM) caused an 
important energetic imbalance evidenced by decreased ATP levels and hyperpolarization 
of the mitochondrial membrane potential (as referred in 5.5) after 24, 48, and 96h of MTX 
incubation in undifferentiated H9c2 cells (Rossato et al., 2013b). In the study of Shipp et al., 
they determined the sensitivity of cultured rat heart cells to MTX treatment. Those cells were 
treated with several drug concentrations (0.05 to 5 μg/mL) for 3h and then medium was 
replaced. ATP levels were measured 72h after initial exposure and a concentration-
dependent decline in ATP levels was observed. ATP suppression was maximal at 72h for 
all MTX concentrations tested; at that time point, there was also a substantial loss of 
spontaneous synchronous contraction in the cultures (Shipp et al., 1993).  
In vivo, male Wistar rats treated with 3 cycles of 2.5 mg/kg MTX at day 0, 10, and 
20 and euthanized on day 48, showed ATP decreases. That ATP decrease was shown to 
be related to mitochondrial disruption (Rossato et al., 2014). Therefore, ATP levels seem to 
be affected by MTX. In our study with MTX an increase in the levels of ATP was reported, 
which seem to be an adaptive response to MTX-incubation. Longer incubation time should 
be tested in our model to assess if it is an adaptive response.  
  
5.7. The role of the cytochrome metabolism on mitoxantrone 
So far the following enzymes were detected in the heart: CYP450, NADPH 
cytochrome reductase, dihydropyrimidine dehydrogenase, epoxide hydrolase, DT-
diaphorase, glutathione S-transferase and UDP-glucuronosyltransferases, among others.  
CYP450 is a superfamily of enzymes that are found in all living organisms. They are 
mixed function mono-oxygenases, which are involved in the oxidative metabolism of a wide 
range of xenobiotics and endogenous compounds (Elbekai and El-Kadi, 2006). Several 
CYP450 have been identified in human (Delozier et al., 2007) and animal heart tissues 
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(Imaoka et al., 2005) as well as different in vitro models such as primary rat cardiomyocytes 
(Thum and Borlak, 2000), immortalized H9c2 cells (Zordoky and El-Kadi, 2007), and 
recently in the atrial HL-1 cell line (Elshenawy et al., 2013).  
Cardiac expression of CYP450 subfamilies identified in mammals includes: CYP1A, 
CYP1B, CYP2A, CYP2B, CYP2D, CYP2E, CYP2J, CYP2R, CYP2S, CYP2U, CYP4A, 
CYP4B, CYP4F and CYP11B (Chaudhary et al., 2009). 
Herein, CYP450 inhibitors, namely metyrapone and 1-aminobenzotriazole, were 
also used to evaluate the role of the CYP450 metabolism on MTX cytotoxicity, since the 
oxidoreductive metabolism of MTX has a significant role on its antitumor effects and recent 
data suggest that MTX metabolism can be related to its cardiotoxicity (Blanz et al., 1991b, 
Bruck and Bruck, 2011, Rossato et al., 2013a). MTX has particular effectiveness in tumours 
with high contents of peroxidases (Blanz et al., 1991b, Bruck and Bruck, 2011). Duthie et 
al. showed that metyrapone is able to prevent the cytotoxic effect of MTX in human liver 
derived HepG2 hepatoma cells, thereby giving further evidence for the participation of the 
CYP450-dependent mixed function oxidase systems on MTX toxicity as referred above 
(Duthie and Grant, 1989). Similar results (metyrapone prevent the cytotoxic effect of MTX) 
were obtained with a rat hepatocytes model (Mewes et al., 1993) and with human breast 
cancer cells (Li et al., 1995) incubated with MTX and CYP450 inhibitors. 
In the study by Rossato et al. the influence of CYP450- and CYP2E1-mediated 
metabolism for the cytotoxicity of MTX was assessed after 96h incubation with MTX (100 
nM and 1 μM) in H9c2 undifferentiated cells. The co-incubation of MTX with CYP450 and 
CYP2E1 inhibitors partially prevented the cytotoxicity caused by the drug, thus highlighting 
that the metabolism of MTX is relevant for its undesirable effects in that model. They proved 
that the bioactivation of MTX mediated through CYP450 and namely through CYP2E1 
metabolism occurs in loco in the cardiomyoblasts and exerts a significant role in the cellular 
damage promoted by MTX (Rossato et al., 2013a). Moreover, they demonstrated that the 
cytotoxicity caused by MTX after S9 hepatic fractions metabolization was significantly 
higher than that observed in the H9c2 cells incubated with MTX without S9 metabolization 
(Rossato et al., 2013a).  
In this thesis, metyrapone and 1-aminobenzotriazole did not prevent of the MTX 
cytotoxicity observed in differentiated H9c2 cells at 48h. The two inhibitors used have 
different mechanisms. 1-Aminobenzotriazole is suicide nonspecific inhibitor. It is a 
metabolism-based inactivator of CYP450 by the mechanism of N-alkylation of heme moiety. 
1-Aminobenzotriazole has been implicated in the inhibition of CYP1A, 2A, 2B, 2C, 2E, 3A, 
4A, and 4B in various organs of different species (Linder et al., 2009). Metyrapone is a 
competitive inhibitor of CYP450-mediated ω/ω-1 hydroxylase activity (Asakura and Shichi, 
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1992), and it is mainly an inhibitor of CYP11B1 (11-β-hydroxylase), but it also inhibits 
CYP11B2 (Sampath-Kumar et al., 1997) and CYP3A4 (Park et al., 2005). 
Rossato et al. described protection with CYP450 inhibitors at 96h in MTT assay 
(Rossato et al., 2013a), whereas in our work the time point was 48h. Thus, longer time point 
may be required for MTX metabolization to form significant amounts of toxic metabolites. 
On the other hand, to the best our knowledge, there are no studies regarding enzyme 
expression in differentiated H9c2 cells and the CYP450 expression can be altered by 
cellular differentiation. In undifferentiated H9c2 cells, there is only few knowledge about 
CYP isoenzymes (Zordoky and El-Kadi, 2007). In the study by Zordoky and El-Kadi, they 
showed that CYP1A1 and 1B1, CYP2B1, CYP2B2, CYP2E1, CYP2J3, CYP2C11, 2C13 
and 2C23 were expressed in H9c2 cells. They concluded that multiple CYP genes are 
expressed in H9c2 cells at comparable level to those expressed in the heart or 
cardiomyocytes (Zordoky and El-Kadi, 2007). However, at this point no study has been 
made to clarify if differentiation alters CYP450 expression, and therefore different 
metabolites can be formed. 
 
5.8. Incubation naphthoquinoxaline in differentiated H9c2 cells 
In this thesis, MTT (Figure 39), LDH (Figure 40), and NR (Figure 41) assays were 
done at 24h and 48h and with different NAPHT concentrations. For NAPHT incubation (1, 
2, and 5 µM) cytotoxicity was time- and concentration-dependent in all assays, being LDH 
the most sensitive test. At 48h, all the concentrations tested caused significant cytotoxicity 
when compared to vehicle cells, being the highest concentration tested (5 µM) able to 
decrease the levels of MTT reduction to values that reached 82.49 ± 4.05%. All the 
concentrations of NAPHT of 1, 2, and 5 µM tested for 24h, caused significant cellular 
membrane integrity loss when compared to vehicle cells. NAPHT at 48h caused a 
significant decrease in cellular integrity, being observed that at 2 µM NAPHT the viability 
was 73.02 ± 2.86% and at 5 µM the viability was 52.07 ± 6.83%, when compared with 
vehicle cells (81.91 ± 1.89%). NAPHT at 2 and 5 µM caused a substantial impairment of 
lysossomal uptake of NR when compared to vehicle cells. At 48h, in the NR assay, the 
H9c2 cells incubated with NAPHT 2 µM (88.82 ± 5.53%) and 5 µM (68.83 ± 6.28%) showed 
a significant lysosome uptake dysfunction when compared to vehicle cells (100.00 ± 
6.18%). 
Two pharmacological active molecules were tested to elucidate the mechanisms 
involved in NAPHT-induced cardiotoxicity, namely 3-methyladenine (an autophagy 
inhibitor) and N-acetyl cysteine (a glutathione precursor and reactive species scavenger). 
3-Methyladenine caused a partial protection to the damage caused in lysossomal uptake 
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by NAPHT (Figure 43). NAPHT caused cardiotoxicity in micromolar concentration being 
autophagy involved. On the other hand, N-acetyl cysteine increased cell death caused by 
2 µM NAPHT (Figure 42). This result may suggest a preconditioning stage that early 
reactive species formation can elicit and that N-acetyl cysteine may avoid (Ferreira et al., 
2013). This mechanism needs further investigation. 
Phase contrast microscopy and several staining’s (Figure 36-38) were used to 
evaluate cytotoxicity of NAPHT. Phase microscopy allowed to observe that NAPHT caused 
cell damage at 24 or 48h incubation. Assessment of mitochondrial membrane potential in 
differentiated H9c2 cells incubated with 2 and 5 μM NAPHT for 12h showed significant 
effects: there was an evident decrease in mitochondrial potential seen in fluorescent 
microscopy (Figure 38). To understand if NAPHT had effects in cellular energetics, 
intracellular ATP levels were measured in H9c2 cell after a 24h incubation. In the NAPHT 
tested concentrations, no significance changes were detected (Figure 44). The work by 
Shipp et al. demonstrated that the metabolite NAPHT had a higher potential on ATP 
depletion than MTX in neonatal rat heart cells and, importantly, that the bioenergetics 
impairment hugely depends on iron availability (Shipp et al., 1993). The work by Shipp a 
co-workers is the only work available so far regarding to NAPHT cytotoxicity and used a 
different model and methodology than the work herein performed.  
 
5.9. Toxicological comparison between mitoxantrone and 
naphthoquinoxaline 
For the highest concentrations of MTX (1, 2, and 5 µM) cytotoxicity was time- and 
concentration-dependent in all assays, being the NR assay more sensitive for the MTX toxic 
effects in H9c2 differentiated cells. On the other hand, for NAPHT (1, 2, and 5 µM) 
cytotoxicity was time- and concentration-dependent in all assays, being LDH the most 
sensitive test. MTX and NAPHT caused a time- and concentration-dependent cytotoxicity, 
although with different sensitivity towards the assays used. 3-Methyladenine caused a 
partial protection to the damage caused in lysossomal uptake by both NAPHT and MTX, 
suggesting that for both molecules autophagy has an important role. N-acetyl cysteine 
increased cell death caused by 2 µM NAPHT, whereas N-acetyl cysteine did not cause any 
alteration in the cytotoxicity observed after MTX incubation. Both molecules caused a 
decreased of mitochondrial membrane potential in differentiated H9c2 cells incubated in 
similar conditions (time and concentration). 
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Regarding ATP levels, drugs had different effects, since NAPHT had no effects and 
MTX caused a significant increase in MTX incubated cells, suggesting an adaptive 
response towards MTX in H9c2 cells.  
MTX and NAPHT share several mechanisms, but differ in other aspects that should 
be further investigated, mainly because the data on NAPHT are very scarce. 
 
5.10. Final conclusions 
Based on the results presented in this study, we propose the following main 
conclusions: 
 With the enzymatic oxidation of MTX, several derivatives could be observed by 
HPLC and two purified derivatives were isolated and identified as NAPHT and NAPHTdi. 
 MTX and NAPHT caused a time- and concentration-dependent cytotoxicity, 
although with different sensitivity towards the assays used. 
 MTX and NAPHT caused cardiotoxicity at micromolar concentration being 
autophagy involved. 
 MTX and NAPHT caused a decreased of mitochondrial membrane potential in 
differentiated H9c2 cells incubated in similar conditions. 
 ATP levels were affected in a different manner in MTX- and NAPHT-incubated H9c2 
cells.  
 Thus, both drugs seem to impair cellular pathways in a dissimilar manner, although 
both cause early mitochondrial depolarization. 
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